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CHAPTER 1 
INTRODUCTION 
Overview of the histological and 
cytological methods to diagnose 
renal allograft rejection 

INTRODUCTION 
Renal allograft transplantation has become a widely accepted method to treat end-
stage renal failure. Over the years patient and graft survival have dramatically increased , 
due to improvement in HLA-typing methods, organ procurement, and organ sharing sche-
mes, resulting in better matching . The introduction of the new potent immunosuppressive 
drugs Cyclosporine A (CsA)3, FK506 , and Mycophenolate Mofetil' has further improved 
the results. The development of the polyclonal antithymocyte globulin (ATG) , and of spe-
cific monoclonal antibodies (MoAbs), such as the anti CD3 MoAb OKT3 ' , has resulted 
in a better targeted control of the immune response. In the pre CsA era, OKT3 was first 
successfully applied to treat established ongoing acute rejection , whereas in later studies 
this MoAb was part of an induction regimen to prevent rejection ' . The results obtained in 
trials with anti CD25, another promising MoAb, reacting with the interleukin-2 receptor 
(IL2-R), were rather conflicting ' . A study with anti CD54, a MoAb against intercellular 
adhesion molecules (anti ICAM-1) demonstrated a better graft survival and a lower inci-
dence of primary non-function in the treated group compared to a control group . 
Although by all these efforts graft survival rates have improved over the last decades, 
long term results are still rather disappointing, since 30-40% of kidneys fail within 5 years 
after first transplantation '. Long term graft survival in CsA treated kidney transplant 
patients is primarily influenced by the occurrence of acute rejection episodes . Adequate 
treatment of acute rejection largely depends on an accurate and early diagnosis. With the 
introduction of more potent basic immunosuppression specific clinical signs and symptoms 
of acute rejection, such as a sudden decrease in urinary output together with fever and graft 
tenderness, that allow for immediate antirejection therapy, have become less frequent. In 
most patients the clinical picture is not so clear-cut, and other causes of declining graft func-
tion, i.e. acute tubular necrosis, CsA nephrotoxicity, infection, surgical complications (post-
renal obstruction by stenosis of the ureter-bladder anastomosis, or stenosis of the renal arte-
ry), or a combination of these factors have to be excluded. Even after the exclusion of 
surgical causes the diagnosis of rejection remains difficult, since no single laboratory test or 
clinical finding is definitively confirmatory. In those cases further investigation by a renal 
allograft core biopsy is required, but sometimes it can even then be difficult to make a 
definite diagnosis on the basis of histology. Especially the introduction of the potent immu-
nosuppressive drug CsA has made assessment and interpretation of the renal graft histolo-
gy more difficult, since the changes caused by CsA nephrotoxicity may overlap with those 
• · . . 17,18 
seen during acute rejection 
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Hütohgy in renal apografi rejection 
The classical findings in the various types of renal allograft rejection have been described 
by Porter in 1967 . He discriminated the following rejection categories: 
1. Acute and immediate rejection, characterized by sludging of red cells and microthrombi 
in the glomeruli, caused by antibodies that are circulating in the recipient at the time of 
transplantation. Today this socalled hyperacute rejection is seldom seen due to extensive 
crossmatching before transplantation. 
2. Acute and early rejection, occurring two to 10 days after transplantation. This is charac-
terized by a dense mononuclear cell infiltration of the tubuli and intertubular space, with 
tubulitis, interstitial inflammation, and edema, together with an infiltration of the arte-
rial wall resulting in an endothelialitis or vasculitis. This phenomenon is largely cell 
mediated and results in tubular necrosis which explains the functional failure of the 
graft. 
3. Acute and later rejection, occurring from 11 days after transplantation onwards, charac-
terized by coating of arteries, arterioles, and glomerular capillaries with immunoglobu-
lins and complement. Platelet aggregates are formed in the glomerular capillaries and 
platelet and fibrin thrombi on the walls of the larger arteries. Cellular infiltration may or 
may not be present. Acute renal failure appears to be caused by the glomerular platelet 
aggregates, while later renal dysfunction is due to narrowing of interlobular arteries fol-
lowing organization of the mural platelet thrombi. 
4. Insidious and late rejection, characterized by subendothelial accumulations of IgM and 
complement on the glomerular capillary basement membranes. These deposits lead to a 
slow impairment of renal function. 
Until recently, this original classification of the various histological rejection types in 
humans has been widely used. At present the classical severe histological appearances have 
become rare, due to the use of more potent immunosuppressive drugs. Another factor that 
complicates the histological diagnosis is that more often renal core biopsies are taken after 
or during an antirejection course to evaluate the histological response to the installed the-
rapy. The change from classical histological lesions to more subtle histological changes 
prompted an international group of renal pathologists, nephrologists, and transplant sur-
geons to propose a new classification schema for the histological changes present in the 
renal allograft, that was intended to be used as a worldwide standard . This schema was 
named the Banff schema, after the place where the first meetings on the new classification 
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system have taken place. Using this Banff schema, it maybe will become possible to get a 
better understanding of the clinical significance of the different histological changes allo-
wing for a more accurate prediction of short term and even, long term graft survival. The 
different histological criteria used in this Banff schema will be summarized in the next para-
graph. 
Histological diagnosis of rejection according to the Banff criteria 
The Banff schema defines histological criteria for rejection, with gradation of patho-
logical changes in grades I-III for both acute rejection and chronic transplant pathology' . 
For the scoring of histological changes in glomeruli, tubuli, interstitium, and vessels, a 
numerical coding system has been added, together with standards for specimen adequacy 
and required staining techniques. In this classification tubulins and intimai arteritis are the 
principal criteria for acute rejection. The differentiation of innocent or borderline infiltra-
tes from grade I acute rejection is mainly based on counts of lymphoid cells per tubular 
cross section (tubular invasion or tubulitis), and estimation of the extent of the interstitial 
infiltrate. Interstitial infiltration cannot be used alone as a specific sign of rejection, since 
several studies on protocol biopsies have shown that focal or mild diffuse infiltrates are quite 
common in well functioning grafts " . The Banff schema was designed such that the false-
positive rate in the diagnosis of rejection would be very low. The following categories are 
distinguished: 
1. normal or "non-specific changes", with normal histology, minor changes or only non-
invasive infiltrates. 
2. Hyperacute rejection with polymorph accumulation in glomerular and peritubular 
capillaries with subsequent endothelial damage and capillary thrombosis within one 
hour post transplantation. 
3. Borderline changes with a mild lymphocyte invasion of the tubules (tubulitis). 
4. Mild acute rejection or grade I rejection, with widespread interstitial infiltrate and 
moderate invasion of the tubules. 
5. Moderate acute rejection or grade II rejection, with a) a widespread interstitial infiltrate 
with severe tubulitis, and/or b) mild or moderate intimai arteritis. 
6. Severe acute rejection or grade III rejection, with a severe intimai arteritis and/or trans-
mural arteritis, fibrinoid changes, and medial smooth muscle cell necrosis, often with 
patchy infarction and interstitial hemorrhage. 
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7. Chronic transplant nephropathy, divided in grade I to III, characterized by interstitial 
fibrosis and tubular atrophy. 
8. Other changes not considered to be due to rejection, such as CsA nephrotoxicity, acute 
tubular necrosis, or recurrence of the original renal disease. 
In the categories 5 and 6 antirejection therapy is recommended. In category 4 treatment is 
advised only if there are also clinical signs of rejection. 
The Banff classification has been widely adopted and is currently used in several multicen-
ter studies. In our studies we used both the original histological diagnosis and the retro­
spectively, and blindly assessed, Banff classification for evaluation of the accuracy of our 
immunohistological and immunocytological diagnostic approaches. 
Immunohistology in renal graft rejection 
Also with the new Banff classification system diagnostic problems in the histological 
examination and interpretation may occur. Additional immunohistological techniques 
might be helpful in discriminating between acute rejection and other causes of renal allo­
graft dysfunction, and thus lead to a better understanding of the intragraft events after 
transplantation. These immunohistological stainings became possible when in the 1980s 
MoAbs specific for the various cell surface antigens of mononuclear cell phenotypes, were 
developed. Initially, attention was mainly focused on the cell type of the graft infiltrating 
cells and on the expression of the parenchymal histocompatibility antigens. Subsequently, 
cell function became the subject of investigation, and recently much attention is given to 
the expression of adhesion molecules. 
Leukocyte infiltration 
Although leukocyte infiltration is a major feature in renal graft rejection, this cellular infil­
tration can also be seen in well functioning renal grafts* " . The extent of interstitial infil­
tration may be influenced by the immunosuppressive drags used . The leukocyte infiltrate 
mainly consists of macrophages and Τ lymphocytes, although studies on the relative import 
tance of both cell types showed discrepancies. Since Piatt presented an immunohistological 
analysis of renal allograft biopsies with MoAbs against the various infiltrating mononuclear 
cells in 1982" , several investigators reported conflicting results in phenotyping of the infil­
trating Τ cells. In the following years some authors considered a predominance of CD8* 
cells in the infiltrate as ominous in view of graft outcome ~ , while others reported CD8* 
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Τ lymphocytes together with macrophages in mild, as well as in moderate, and in severe 
rejection . Furthermore, immunohistological analysis of biopsies from renal transplant 
recipients receiving anti Τ cell receptor MoAb therapy (OKT3), has demonstrated that 
CD3* Τ cells persist in the graft following such therapy, but that there may be a phenoty-
pic shift to CD8* CD45R* (suppressor/inducer Τ cells) ' . Several workers have reported 
an increase of macrophages in renal biopsy specimens with signs of acute rejection* ' 
and this increase has been used in the cytological diagnosis of rejection in fine needle aspi­
rates of the grafts . For the histological diagnosis of acute rejection this increase has not 
received much attention, probably because of the variable and usually weak staining of renal 
allograft macrophages with most monocyte/macrophage MoAbs. 
HLA-DR expression 
Hall et al. first reported HLA class II (HLA-DR) antigen induction in renal allograft rejec­
tion , a finding that was confirmed by others " . On the other hand, Fuggle et al. obser­
ved increased class II antigen expression in the absence of clinical rejection, and, by con­
trast, also the absence of class II antigen expression during acute rejection ' . This finding 
was later confirmed described by Raftery et al. Furthermore, the degree of H1A-DR 
expression can be influenced by the immunosuppressive regimen . 
Adhesion molecules 
Adhesion molecules are essential for nonspecific binding between leukocytes and for bin­
ding of leukocytes to cells of non-leukocyte origin. In normal kidneys the intercellular 
adhesion molecule ICAM-1 is expressed on the endothelium of peritubular and glomeru­
lar capillaries, whereas the vascular adhesion molecule VCAM-1 and the endothelial leuko­
cyte adhesion molecule ELAM-1 or E-selectin, which mediates the adhesion of monocytes 
and resting CD4+ memory Τ cells to activated endothelium, are absent " . In rejection, 
increased expression of ICAM-1 is observed on the endothelium and on the tubular epi­
thelial cells , while VCAM-1 expression appears on the endothelium, and is correlated to 
the extent of Τ cell infiltration . A variable change is seen in the E-selectin expression on 
the endothelium, but this can also be present in case of acute tubular necrosis (ATN) . In 
renal allograft biopsies, however, increased tubular ICAM-1 expression can be seen without 
evidence of rejection, which limits the diagnostic value of this parameter . 
Activation markers 
Using IL2-R expression as a marker of lymphocyte activation, Séron et al. demonstrated an 
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association of rejection with the proportion of activated Τ cells in transplant biopsies. They 
found a similar association with the transferrin receptor and Ki-67, which are both markers 
of cell proliferation '. The percentage of memory Τ cells, defined by loss of the CD45R sur­
face antigen, has been shown to be much higher in populations of Τ cells infiltrating renal 
allografts than in the peripheral blood of the same patients . For routine daily clinical prac­
tice, however, these markers are not useful in discriminating rejection from other causes of 
renal graft dysfunction. 
For all these new immunostaining techniques that might be helpful in diagnosing 
rejection, a renal allograft biopsy is required. This procedure is not without risks. It may 
cause severe bleeding, with incidentally even loss of the kidney . Although the introduc­
tion of the ultrasound-guided biopsy has enabled the clinician to locate the kidney more 
precisely, less hazardous methods, such as the fine needle aspiration biopsy, and examina­
tion of the urine and of the peripheral blood, have been developed in order to obtain insight 
in the intragraft events without harming the kidney. 
Fine Needle Aspiration Biopsy of the renal allograft 
The method of the fine needle aspiration biopsy (FNAB) of the renal allograft, that 
was introduced by Häyry and von Willebrand, allows for a quick, safe and frequent, even 
daily, sampling of cells from the renal allograft . However, the information derived from 
the FNAB is more limited than that obtained from a core biopsy . A differential count of 
leukocyte populations in the aspirate is compared with that in peripheral blood, resulting 
in the increment. The diagnosis of rejection depends to a large degree upon identification 
of inflammatory cells such as lymphoblasts, macrophages, and plasma cells, that are indi-
cative of rejection, although differentiation of these cells from activated lymphocytes and 
monocytes is not always easy. For the cell types assumed to be of most importance in acute 
cellular rejection correction factors have been introduced that correlate with their relative 
value for the diagnosis. The sum of the different corrected increments leads to the total cor-
rected increment, that is indicative for acute rejection when above a certain limit. Besides a 
good sensitivity and specificity " the method is reported to have a good reproducibili-
ty ' , with the highest accuracy in the first three months after transplantation. Possibly, this 
accuracy can be increased by combining conventional cytology with immunocytological 
stainings, as reported by Bishop et al. By combining semiquantitative scores for HLA-DR 
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expression on renal tubular cells and mononuclear cells with a score of Tll-positivity of 
activatedT cells, they were able to correcdy diagnose 32 of 34 cases of renal allograft rejec-
tion . An advantage of this technique is that a much larger number of cells of the aspirate 
can be assessed: 500 to 3000 cells by immunostaining as compared to 200 cells by conven-
tional FNAB examination. Furthermore, this technique does not require the cytological 
skills that are demanded by the method of Hayry and von Willebrand. 
A major limitation of the FNAB in comparison with histology, however, is its inabili-
ty to diagnose a vascular rejection, acute as well as chronic vascular rejection, chronic CsA 
nephrotoxicity, and recurrences of the original renal disease. Although the FNAB cannot 
replace a core biopsy, it could be valuable for the continuous monitoring of the renal graft 
in the first posttransplantation period ' ' . The same problems as encountered in core 
biopsies, however, are reported: Ubhi et al. frequently observed increased corrected incre-
ments without clinical signs of rejection during conversion from CsA to azathioprine treat-
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ment . 
Urine cytology in renal allograft rejection 
Already in the early years of renal transplantation cytological examination of the urine 
has been used to monitor the events occurring in the graft " ' . In 1963 Hume et al. repor-
ted that changes in the urinary sediment of transplant patients can be diagnostic for rejec-
tion, and can even have a predictive value before deterioration of graft function or other cli-
nical signs of rejection are demonstrable . An advantage of this noninvasive diagnostic 
method is that serial testing is possible, giving quick results, without any risk, neither for 
the patient nor for the graft. In the earliest studies, mostly in the 1960s and early 1970s, 
most investigators considered lymphocyturia as a marker of acute rejection ' " . 
Specimens were usually prepared by simple centrifugation or by membrane filter techniques 
with minimal effort at quantitation. In 1977 Schumann introduced the cytocentrifuga-
tion technique to prepare urine specimens and described the cytological characteristics of 
the urine in kidney transplant patients. He and others considered the presence of degene* 
rated or necrotic tubular epithelial cells (TEC), especially collecting duct cells, a better mar-
ker for acute rejection than lymphocytes ' / + , while another group of investigators found 
the combination of increased lymphocyturia with increased excretion of TEC the hallmark 
of rejection ' . Several authors, however, reported conflicting results on lymphocyturia 
after transplantation: Kline et al. could not demonstrate a correlation between lymphocyte 
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excretion in the urine and status of the graft , while others demonstrated lymphocyturia in 
situations other than rejection * . Furthermore, the presence of large numbers of desqua­
mated TEC is reported during graft dysfunction from other causes than rejection, such as 
acute tubular necrosis and CsA nephrotoxicity . The major problem in these early con­
ventional cytological studies was the difficulty to discriminate lymphoid cells from other 
mononuclear cells or even from TEC among the frequently partly degenerated cells in the 
urinary sediment. Since these early studies several attempts have been made to overcome 
this problem by using special staining techniques, such as the methylgreen pyronine stai­
ning ' ' ' , or later, by using MoAbs against specific cell markers to look more precisely at 
the excreted urinary cells ' . 
Peripheral blood lymphocytes in renal albgraft rejection 
Over the years several conflicting reports have been published either emphasizing or 
denying the utility of different immune variables demonstrable in the peripheral blood for 
the diagnosis of renal allograft rejection. The variable rejection markers that have been studied 
are Τ helper/suppressor ratios , eosinophilic neutrophils , natural killer cell levels , 
plasma IL2-R levels , IL2-R expression on Τ cells, alone or in combination with HLA-
DR expression on Τ cells , serum interleukin-6 levels in combination with CsA trough 
levels , human renal tubular epithelial antigen in serum , and circulating ICAM-1 
levels . The problem of all these studies is that they describe correlations between rejec­
tion markers and clinical events in a statistical sense only, which is of little practical value 
for the individual patient . Furthermore, the comparison and interpretation of the diffe­
rent studies is problematic, because of differences in immunosuppressive regimens, cell enu­
meration techniques, MoAbs that are applied, and methods used for analyzing the data . 
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OUTLINE OF OUR STUDIES ON NEW TECHNIQUES IN THE DIAGNOSIS OF 
ACUTE REJECTION 
From the previous section we may conclude that there is no ultimate test to diagnose 
rejection of renal allografts with sufficiently high accuracy and without risk to the graft. We 
have, therefore, developed and studied two new, additional diagnostic approaches. 
PARTI 
Evaluation ofimmunohistological staining of macrophages 
We investigated the diagnostic value of immunostaining of renal allograft biopsy sec-
tions with the new antimonocyte/macrophage MoAb WT14, directed against the CD14 
antigen. This antibody was developed in our laboratory. By using an indirect immuno-
peroxidase technique we tested whether the presence of macrophages in the renal allografts 
could be used as a marker for acute rejection. Data on WT14 staining in normal kidneys, 
in rejecting renal allografts, in grafts with CsA nephrotoxicity, and in native kidneys with 
various diseases, are given in chapter 2. The rejecting grafts showed a characteristic peritu-
bular increase of WTl4-positive cells. Whereas the anti CD14 MoAb WT14 can only be 
applied to cryostat sections, which sometimes requires an additional renal core biopsy, the 
antimonocyte/macrophage (anti CD68) MoAb KP1 can be applied to routinely processed, 
Bouin-fixed, paraffin-embedded renal tissue '. We tested in a subsequent study, described 
in chapter 3, whether the peritubular increase in macrophages, the pattern seen in the 
WT14 studies, can also be demonstrated on these routinely processed biopsies, and 
whether this KP1 staining can be a helpful adjunct in the immunohistological diagnosis of 
acute rejection. In a separate study we tested whether the extent of peritubular WT14 positi-
vity in core biopsies could be used as an independent marker for acute rejection (chapter 4). 
PART2 
Evaluation ofhistohgical criteria, as proposed in the Banff Classification, for the diagnosis 
of rejection 
The aim of this study was to determine the relative weight of the different histologi-
cal lesions for the final diagnosis, and possibly for the prognosis of the graft. We therefore 
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reviewed a series of renal allograft biopsy specimens without knowledge of the clinical data 
and compared histological diagnoses with the final clinical diagnoses. To reach a standardized 
histological diagnosis we used the Banff schema with its semiquantitative scores for the 
different histological lesions that can be found in the renal allograft. This allowed us to eva­
luate the Banff criteria in clinical practice (chapters 5 and 6). We also used this Banff clas­
sification schema in the validation of KP1 (CD68) and WT14 (CD14) staining, and com­
pared the Banff diagnosis with the definitive clinical diagnosis in a series of renal allograft 
biopsies performed during a three years period. 
PART3 
Evaluation of urinary immunocytology 
We developed a standard protocol for cytological and immunocytological examination 
of urinary sediments in renal graft recipients. We investigated whether Τ lymphocytosis 
together with increased HLA-DR expression on TEC, as seen in conventional core biopsy 
specimens and in FNABs, can also be demonstrated in urinary sediments and can serve as 
rejection parameters. Since experimental data suggest that CsA therapy causes downregula-
tion of HLA-DR expression we also studied the effect of conversion of CsA to azathioprine 
therapy on the reliability of increased HLA-DR expression on TEC as a sign of rejection 
(chapter 7). In a group of randomly chosen renal allograft recipients with declining graft 
function we determined whether the immunocytological findings in the urine could dis­
criminate between rejection and other causes of graft dysfunction (chapter 8). Finally, we 
studied the value of sequential immunocytological examination of the urinary sediment for 
monitoring of rejection in renal transplant patients (chapter 9). For this, urinary sediments 
of 121 patients were examined at regular intervals (from twice weekly to once monthly) 
during six months after transplantation. Retrospectively, we evaluated the blindly scored 
cytological diagnoses with regard to the accuracy of the diagnosis of rejection, and the 
accuracy of the diagnoses in stable patients, with emphasis on the predictive value of a posi­
tive and a negative cytological diagnosis. 
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ABSTRACT 
Since acute interstitial rejection (AIR) of renal allografts is accompanied by an increase 
of macrophages in the graft the diagnostic value of immunohistological staining of biopsy 
specimens with WT14, a new monoclonal antibody of the CD 14 cluster directed against 
monocytes/macrophages, with increased affinity for activated cells, has been tested retro-
spectively. With an indirect immunoperoxidase technique on frozen sections a diffuse inter-
stitial increase of WTl4-positive cells was seen, with a characteristic peritubular pattern, in 
all 44 patients with clinically and histologically proven AIR. This pattern was not seen in 
normal kidneys (n=10), or in biopsy specimens from patients with proven Cyclosporine 
nephrotoxicity (n=9), chronic vascular rejection (n=13), or various other renal diseases 
(n=60). Comparative staining with other monoclonal antibodies against 
monocytes/macrophages showed a variable, mostly weak or less specific staining pattern 
than did WT14. The increased staining with WT14 proved to be a better indicator of AIR 
than increased HLA-DR staining on tubular epithelial cells. 
INTRODUCTION 
Adequate treatment of acute rejection after renal transplantation greatly depends on 
accurate and early diagnosis. In some patients clinical signs and symptoms are sufficiently 
specific to justify immediate antirejection therapy. However, in many patients the clinical 
picture is equivocal and histological examination of a transplant biopsy specimen does not 
always give a definitive diagnosis. The worldwide use of Cyclosporine (CsA) as immuno-
suppressive treatment has, together with improvement in graft survival, added to the diffi-
culties in histological assessment of the cause of deteriorating renal graft function, since the 
histological changes caused by CsA nephrotoxicity may overlap with those of rejection ' . 
Because rejection is accompanied by increased expression of class II major histocom-
patibility complex antigens on tubular epithelial cells immunohistological staining of renal 
biopsy specimens with HLA-DR antibodies has been used to diagnose rejection, especially 
in patients in whom the differentiation between CsA nephrotoxicity and rejection is diffi-
cult . However, such an increase in class II antigens is not specific for rejection: it also occurs 
when there is increased interstitial infiltration due to other causes and during viral infec-
tions , and is not invariably present in rejection . Rejection can also be demonstrated by the 
presence of T-lymphocytosis in the interstitial cellular infiltrate, especially in fine needle 
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aspiration biopsy specimens, where this index is of proven value to distinguish between 
acute interstitial rejection (AIR) and CsA nephrotoxicity or acute tubular necrosis ' . In his­
tological material, demonstration of increased numbers of Τ cells is of limited value since 
these ceils predominate in most infiltrates due to causes other than rejection. 
Several workers have reported an increase of macrophages in renal biopsy specimens 
with signs of AIR , and this increase has been used in the diagnosis of rejection with fine 
needle aspiration . However, for the histological diagnosis of AIR, this increase has not 
received much attention, probably because of the variable and usually weak staining of renal 
allograft macrophages with most monocyte/macrophage monoclonal antibodies (MoAbs). 
We report here a novel MoAb, WT14, that recognises the CD 14 cluster of differentiation 
and shows a consistent, intensive binding to interstitial macrophages in AIR. 
MATERIAL AND METHODS 
Monocbnal Antibodies 
WT14 was developed in our laboratory by immunisation of a BALB/c mouse with 
human monocytes. In cell suspensions this murine IgGl antibody reacts with human 
monocytes and macrophages, but not with В or Τ lymphocytes, or granulocytes. The anti­
body binds to CD14 transfectants (S. Goyert, New York, andTh. Look, Memphis, personal 
communication). In cell suspensions the staining of monocytes shows a membranous dis­
tribution. WT14 does not completely overlap with other CD14 MoAbs: when monocytes 
are first incubated with WT14 there is co-capping with other CD 14 antibodies, but when 
WT14 is added after capping of the C D 14 antigen with another CD 14 antibody, mem­
brane staining is still observed. This staining suggests a broader specificity or a higher affini­
ty ofWTl4. The antigen recognised by WT14 is not expressed by immature monocytic cell 
lines (eg, HL60, U937). When monocytes are cultured in vitro, the expression of the anti­
gen increases strikingly, and this increase is even more pronounced when the cells are cul­
tured in the presence of 1,25 dihydroxy-vitamin D } . In tissue sections WT14 reacts with 
intravascular monocytes, histiocytes, tissue macrophages, dendritic cells, and in a variable 
and usually weak manner with endothelial cells of medium-sized and small blood vessels. 
The staining in histological sections has a cytoplasmic appearance, with a rim of increased 
intensity at the periphery of the cell. 
The staining pattern of WT14 was compared with that of the following MoAbs 
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reacting with monocytes and macrophages: for C D 14, My4, and Mo2 (Coulter, Hialeah, 
Fl, USA), UCHM1 and FMC17 (Sera Labs, Crawley Down, England), and LeuM3 
(Becton Dickinson, Mountain View, Ca, USA); for CD1 lb/CD 18, Mol (Coulter) and 
OKM1 (Ortho, Raritan, NJ, USA); for CDl lc/CD18, LeuM5 (Becton Dickinson); and 
for CD 15, LeuMl (Becton Dickinson) and the non-clustered Dako-Mac, clone EBM/11 
(Dako, Denmark). The specificities and tissue distributions of these antibodies have been 
reported previously . A MoAb against a non-polymorphic HLA-DR determinant (clone 
L243) was obtained from Becton Dickinson, and T i l (clone 3PT2H9), a CD2 MoAb 
reacting with a protein associated with the E rosette receptor of Τ lymphocytes, from 
Coulter, For specific identification of the endothelial cells of the peritubular capillaries we 
used the MoAb PAL-E16. 
Renal tissues 
Renal biopsies of transplant recipients with a clear-cut diagnosis of AIR (n=44) or CsA 
nephrotoxicity (n=9) were selected retrospectively from clinical and pathological records. The 
diagnoses were made on the basis of clinical signs and symptoms, histology, and a good 
response to antirejection therapy or to lowering of the CsA dose. All patients were initially 
treated with CsA, then by azathioprine and prednisone 12 weeks after transplantation '. 
Biopsy specimens from patients with a histological diagnosis of AIR were selected on the basis 
of the presence of a diffuse interstitial mononuclear infiltrate with oedema, infiltration of 
mononuclear cells in tubular epithelial cells, focal destruction of tubular basement membrane, 
and in many patients degenerative changes in tubular epithelial cells . In 26 of 44 patients 
the renal biopsy had been done within the first 3 months after transplantation (mean 32.5 
days, SD 17.3). In the remaining 18 patients AIR had occurred at a later stage (169.9 [84.9] 
days after transplantation). CsA nephrotoxicity was diagnosed when the renal biopsy speci­
men showed the tubular, interstitial, or vascular changes described by Mihatsch et al. , in the 
absence of notable interstitial infiltrates. These specimens had been taken between 8 and 30 
days after transplantation (16.1 [7.5] days). A histological diagnosis of chronic vascular rejec­
tion (n=13) was made on the basis of the presence of obliterating and sclerosing vascular 
lesions, in most cases accompanied by interstitial fibrosis and signs of ischaemia . Clinically, 
the patients in this group had a gradual loss of renal function. Controls included normal renal 
tissue taken from tumour nephrectomy specimens from 10 patients, and renal biopsy speci­
mens from 60 non-transplanted patients with various renal diseases (Table 1). 
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Histology and immunohistohgy 
For histological examination 2 μιτι paraffin sections of Bouin-fixed renal tissue were 
stained with haematoxylin and eosin, periodic acid-Schiff, silver methenamine, and chro­
me aniline blue. For immunohistology 4 μπι cryostat sections of fresh-frozen tissues were 
air dried, fixed in acetone for 10 min, and incubated with the various monoclonal antibo­
dies in appropriate dilutions for 60 min at room temperature. After three washings with 
phosphate buffered saline (PBS) the sections were incubated with peroxidase-labelled rab­
bit anti-mouse Ig (Dako, 1:80), and, after three further washings with PBS, colour was 
developed with diaminobenzidine (0.5 mg/ml). Sections were counterstained with hae­
matoxylin. Sections first incubated with T i l (1:40) and PBS were positive and negative 
controls, respectively. The sensitivity of our two-layer routine technique was compared with 
that of a trilayer technique in which an extra incubation step (30 min) with peroxidase-
labelled swine-anti-rabbit Ig (Dako, 1:20) was added after the peroxidase-labelled rabbit 
anti-mouse serum. The staining pattern of WT14 was compared semiquantitatively with 
that of the other monocyte/macrophage MoAbs in serial sections. To test for overlap of 
W T l 4 staining with anti-HIA-DR or with the endothelial cell marker PAL-Ε, frozen sec­
tions were incubated with WT14 and tetrarhodamine isothiocyanatelabelled rabbit anti-
mouse Ig serum (Dako, 1:80) followed by incubation with fluorescein isothiocyanate 
(FITQ-labelled PAL-E (1:50) or FITC-labelled anti-HIA-DR (1:50). 
The intensity of the HIA-DR staining was graded semiquantitatively as mild, mode­
rate, or strong, with the staining intensities of the peritubular capillaries and interstitial cells 
as an internal reference. Since normal kidneys frequently show a mild expression of HLA-DR 
antigens on tubular epithelial cells, only biopsy specimens that showed unequivocally in­
creased staining to at least a moderate degree were scored as having increased HLA-DR 
expression. 
RESULTS 
Table 1 shows WT14 and anti-HLA-DR staining in normal kidney, and in renal 
biopsy specimens from patients with a diagnosis of rejection, CsA nephrotoxicity, and other 
diseases. In normal renal cortex WT14 stained only dispersed interstitial cells that resem­
bled dendritic cells, mostly lying close to the peritubular capillaries (Figure 1). The endo­
thelial cells of the peritubular capillaries, which showed intense staining with PAL-Ε, were 
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Table 1 
Patients positive for WT14 and HLA-DR staining in renal biopsy specimens. 
Histological diagnosis 
WT14 
diffusely 
increased 
0/10 
44/44 
6713 
0/9 
0/13 
0/10 
0/11 
0/12 
177 
577 
HLA-DR 
increased 
onTEC8* 
0/10 
40/44 
11/13 
5/8 
9/13 
9/10 
4/10d 
7/11d 
6/7 
4/7 
Normal kidney 
Acute interstitial rejection (AIR) 
Chronic vascular rejection 
Cyclosporine nephrotoxicity 
Minimal change nephropathy 
Focal segmental glomerulosclerosis 
Membranous glomerulonephropathy 
IgA nephropathy 
Mesangiocapillary glomerular nephritis 
Tubulointerstitial nephritis 
a TEC = tubular epithelial cells. 
b Only increased staining to at least moderate degree scored as positive. 
о Positive staining In confluent patchy areas of interstitial infiltration, leading to semi-diffuse increase 
but without characteristic peritubular distribution of AIR. 
d Insufficient frozen material from 1 patient to repeat equivocal first test. 
Table 2 
Staining patterns of antibodies against human monocytes/macrophages in renal biopsy specimens. 
Staining pattern Monoclonal antibodies* 
Consistent, intensive staining of 
interstitial cells 
Variable, weak, or negative staining 
of interstitial cells 
Variable staining of TEC 
Background staining 
WT14, Dako-Mac (EBM/11) 
My4, LeuM3, FMC17, UCHM1, LeuM5, OKM1, Mo1, 
Mo2 
Dako-Mac, My4, FMC17, Mo1, Mo2, LeuM1, LeuM3 
UCHM1,FMC17, OKM1,My4 
a For specificities see ref 13-15. 
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Figure 1 
Photomicrographs ofWTlé staining in normal kidney (left, χ 80) and in renal allograft 
with acute interstitial rejection (right, χ 40). Arrows: positive dispersed interstitial cells with 
the morphology of dendritic cells; G: glomerulus; left figure, immunoperoxidase and haema-
toxylin; right figure, diffuse increase ofWTl4-positive celh around negative tubules, immuno­
peroxidase without counterstain. 
negative for WT14, with weak positivity only if the enhanced tfilayet technique was used. 
In the normal kidney glomeruli only sporadic WTl4-positive cells were seen, situated in 
the mesangium. Double staining with WT14 and PAL-Ε confirmed that the dendritic 
WTl4-posidve cells were often in close contact with the peritubular capillaries. Double 
staining with WT14 and anti-HLA-DR showed that most WT14-positive cells were posi­
tive for HLA-DR. 
All 44 renal biopsies with AIR showed a diffuse increase of WTl4-positive cells, situ­
ated in the interstitium and mostly in close apposition to the tubular basement membrane, 
forming semicontinuous masses around the negative tubules (Figure 1). This characteristic 
staining pattern was, in all patients, easily demonstrable with the simple two-layer techni-
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que. The positive cells had oval nuclei and a moderate amount of ill-defined positively stai-
ning cytoplasm, consistent with the histological appearance of tissue macrophages. In dou-
ble immunofluorescence staining the WTl4-positive cells were seen between the tubular 
basement membrane and the peritubular capillaries. Staining with anti-HLA-DR showed, 
apart from positivity of the interstitial infiltrating cells and the capillaries, a moderately or 
strongly increased expression on tubular epithelial cells in 9 1 % of patients (Table 1). 
In 7 of 13 patients with chronic vascular rejection only a mild, focal increase of 
WTl4-positive cells was seen. In 6 patients confluent patchy accumulations of positive cells 
were found in areas where a mild interstitial infiltrate was present. However, the diffuse 
peritubular positive staining seen in AIR was not present. HLA-DR expression on tubular 
epithelial cells was greatly increased in 9 of 13 patients, and moderately increased in 2. 
In 2 of 9 patients with CsA nephrotoxicity biopsy specimens showed a WT14 staining 
pattern identical to that in normal kidneys. In the other patients dispersed local increases 
of positive cells were seen, but these were very limited and never resembled the diffuse peri-
tubular positivity seen in AIR. In contrast, of 8 specimens stained with anti-HLA-DR, 5 
showed a definite increase in HIA-DR expression on tubular epithelial cells, 3 to a pro-
nounced and 2 to a moderate degree. None of the specimens from patients with minimal 
change nephropathy, focal segmental glomerulosclerosis, membranous nephropathy, or IgA 
nephropathy showed more than a slight or focal increase in WTH-positive cells; in con-
trast, increased HIA-DR expression in tubular epithelial cells was frequently seen. Only 
where mesangiocapillary glomerulonephritis and tubulointerstitial nephritis were accom-
panied by extensive interstitial infiltrates did we find confluent patchy increases of WT14 
staining, which, however, did not show the diffuse peritubular localisation seen in AIR. 
To compare WT14 staining with that of other monocyte/macrophage antibodies we 
examined serial sections in 3 normal kidneys and 4 from patients with AIR. Most anti-
bodies showed either a variable and weak positivity on WTl4-positive cells or a negative 
reaction, whereas in some patients local positivity with tubular epithelial cells or back-
ground staining was also seen (Table 2). Dako-Mac (EBM/11) was the only other antibody 
to show a strong and stable positive staining of interstitial cells, generally equal to or some-
what more intense than that with WT14. However, Dako-Mac was also positive for tubu-
lar epithelial cells, as has been reported earlier , with increased intensity in degenerated and 
necrotic cells. Thus there was a loss of histological detail that made the overall picture more 
difficult to interpret than that of WT14. 
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DISCUSSION 
Our results show that in biopsy specimens from all patients with AIR, immunohisto-
logical staining with the CD 14 MoAb WT14 shows a characteristic increase of positive peri­
tubular cells that is not found in CsA nephrotoxicity or non-transplanted patients with 
various renal diseases. WT14 combines an intensive and stable staining of the peritubular 
infiltrating cells, in a simple two-layer technique, with negativity for tubular epithelial cells, 
and little or no background staining. Of the other MoAbs only Dako-Mac showed much the 
same stable intensity, but its binding to tubular epithelial cells makes interpretation less easy. 
WT14 staining seems to be a more specific marker for rejection than the expression of 
HLA-DR antigens on tubular epithelial cells, which we found to be increased in many 
other lesions. In contrast to Milton and colleagues' findings in the rat and those of Barrett 
et al. in human kidney, we showed increased HLA-DR expression on the tubular epithe­
lial cells in over half the patients with CsA nephrotoxicity. This finding might be related to 
the early timing of the biopsies: in 4 of the 5 positive patients the biopsy was done within 
3 weeks after transplantation, and Fuggle et al. , in 4 2 % of serial biopsy specimens from 
CsA-treated patients 21 days after transplantation, have shown increased HLA-DR expres­
sion on tubular epithelial cells irrespective of whether there were clinical signs of rejection. 
All our patients responded well to lowering of the CsA dose and did not need antirejection 
therapy within 2 months after biopsy. Thus the level of HLA-DR expression on tubular 
epithelial cells is of limited value to differentiate AIR from CsA nephrotoxicity. In contrast, 
WT14 staining clearly distinguished between these two conditions, by the absence of 
diffusely increased positive cells in all patients with CsA nephrotoxicity. 
Our findings of increased HLA-DR expression on tubular epithelial cells in renal 
diseases in non-transplanted kidneys, especially in those with minimal interstitial infiltrate, 
need further study. The few reports on this subject have mostly been of small series, in 
which no increased class II expression was recorded ' ' . We avoided overestimation of 
HLA-DR positivity by scoring as positive only patients with unequivocally increased stai­
ning to at least a moderate degree, and by excluding those with only mild positivity. 
From the specificity of the WT14 antibody, the staining patterns with other mono» 
cyte/macrophage MoAbs, and the negativity of the WTl4-positive cells for PAL-Ε and 
T l 1, we can conclude that AIR is accompanied by a massive interstitial increase of cells of 
the monocyte/macrophage lineage that seem to be implicated in the rejection process. The 
presence of many macrophages in acute rejection has been reported often, both in biopsy 
material of renal ' or cardiac" allografts and in cell suspensions of rejected tissues " ' . 
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The typical peritubular localisation of these cells in renal allografts has also been noted ' . 
However, an increase in macrophages in the diagnosis of rejection has not received much 
attention, which, especially in renal biopsy specimens, may be because of difficulties in visu­
alisation. In suspension, macrophages are easily recognised, which accounts for their early 
detection in cell suspensions obtained from renal grafts ' and their diagnostic value in fine 
needle aspiration biopsy. In contrast, in routinely stained histological sections macrophages 
are inconspicuous. In many of our patients with AIR the number of WTl4-positive cells 
was much higher than expected from routine sections. Most MoAbs directed against mono­
cytes/macrophages either gave variable or weak staining, or showed insufficient contrast. 
This finding may be attributable to the release of antigens, background staining, or staining 
of tubular epithelial cells, difficulties that have also been reported by others . The variabi­
lity of the staining intensities of monocyte/macrophages antibodies at different stages of 
activation of the cells '' may add to these difficulties. Many MoAbs that generally react 
with macrophages give negative or weak results in renal allograft rejection . The fact that 
WT14 binding of monocytes greatly increases after culture in the presence of 1,25 dihy-
droxy-vitamin D 3 indicates that the expression of the antigen recognised by WT14 in­
creases with activation, which might account for the high affinity of WT14 for allograft 
macrophages. 
The appearance of large numbers of macrophages in acute rejection suggests a possi­
ble role for these cells as effector cells in the rejection process. Τ cells are regarded as the 
essential effector cells in graft rejection, but what are the mechanisms leading to the even­
tual tissue necrosis in the continuing reaction? And is the ultimate cell lysis effected by cyto­
toxic cells or can it also be induced by other cells, such as macrophages in a delayed type of 
hypersensitivity (DTH)-like mechanism of tissue destruction" ? The direct apposition of 
the macrophages to the tubular basement membrane in AIR indicates a direct damaging 
effect of these cells on the parenchymal tubular epithelial cells. Such a mechanism has also 
been assumed to explain the presence of abundant macrophages in direct contact with myo­
cardial cells in the rejection of rat cardiac allografts . In accord with the findings of 
Hancock et al. we repeatedly found a pronounced increase in macrophages only when a 
mild interstitial infiltrate was seen in routine sections. This finding suggests that macro­
phages become implicated in graft rejection at an early stage, and that their presence does 
not necessarily indicate an advanced or irreversible stage of AIR as is currently assumed . 
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ABSTRACT 
Acute interstitial rejection (AIR) of renal allografts is accompanied by a characteristic 
peritubular increase in macrophages, which can be identified with the CD 14 monoclonal 
antibody (MoAb) WT14 in cryostat sections. Since frozen tissue is not always available, we 
tested whether this increase can also be demonstrated in Bouin-fixed, paraffin-embedded 
biopsies, using the CD68 anti-macrophage MoAb KP1, which can also be applied to 
paraffin sections. Sections of 16 biopsies with AIR and 11 controls were stained with KP1. 
In 25 of the 27 biopsies, macrophages were strongly positive for KP1. Two AIR biopsies 
were completely negative, probably due to prolonged fixation. In the remaining 14 AIR 
biopsies, the number of KP 1-positive cells was significantly higher than in the controls 
(1184+410 per mm (mean+SD) vs 112±126 per mm"). We conclude that, especially in 
cases in which frozen tissue is not available, the demonstration of increased numbers 
of monocytes/macrophages with MoAb KP1 can be a helpful adjunct in the histological 
diagnosis of AIR in routinely processed renal biopsies. 
INTRODUCTION 
In renal transplantation it can be very difficult to differentiate, either clinically or his­
tologically, acute interstitial rejection (AIR) from other causes of declining graft function. 
The use of Cyclosporine (CsA) as an immunosuppressive treatment has added to the 
diagnostic problems since the histologic changes caused by CsA nephrotoxicity can overlap 
with those in AIR " . Therefore, in addition to the usual histological criteria , immuno-
histological findings, such as the presence of Τ lymphocytosis and increased expression of 
HLA-DR on tubular epithelial cells (TEC), have been used as diagnostic markers for 
AIR ' ' . In difficult cases, however, even these markers are not specific enough to yield a 
definitive diagnosis. There is an increase of Τ lymphocytes in most cases of interstitial inf­
lammation, and the upregulation of HLA-DR expression is not specific for AIR either, as 
it also occurs during viral infections and is not invariably present in AIR . 
Several authors have shown that AIR is accompanied by an increase in macropha­
ges™ ' , but until recently this finding did not receive much attention for diagnostic pur­
poses, probably due to difficulties in visualization in histological sections . A new anti-
CD14 antibody, WT14, has shown such intensive and characteristic binding to interstitial 
macrophages in AIR that it could be used as a marker for rejection with better specificity 
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than increased HLA-DR expression on TEC . However, like most MoAbs, WT14 can only 
be applied to cryostat sections. Since the small size of renal core biopsies does not always 
allow for separation of part of the material for immimohistology, it would be advantageous 
to have an anti-macrophage antibody at one's disposal that reacts with antigenic structures 
that are resistant to routine fixation and embedding in paraffin. For routine fixation of renal 
tissue, either buffered formalin or Bouin's solution are used. Bouin's solution ' is the opti­
mal fixative for the methenamine silver stain and trichrome stains, necessary for histologi­
cal examination of renal tissue. This fixative, with a pH of 1.8, has an adverse effect on the 
preservation of antigenic structures, even more so than neutral-buffered formalin. In the 
present study, we tested whether the new anti-monocyte/macrophage MoAb KP1, which 
can be applied to routinely processed tissues , can be used as a marker for the diagnosis of 
AIR in routinely processed, Bouin-fixed, paraffin-embedded renal allograft biopsies. 
MATERIALS AND METHODS 
Antibodies 
The MoAb KP1 (CD68, Dakopatts, Denmark), raised against a lysosomal fraction of 
human lung macrophages, recognizes a fixation-resistant epitope on monocytes, tissue 
macrophages and granulocyte precursors, both in cryostat sections and in tissues fixed in 
formalin or Bouin's solution . In macrophages and monocytes, KP1 gives a fine to coarse 
granular cytoplasmic staining pattern. A weak to negative staining is seen in granulocytes, 
whereas lymphocytes are negative . The antibodies UCHL1 (CD45RO) and L26 (CD20; 
both from Dakopatts, Denmark) react in paraffin sections with Τ cells and В cells respecti­
vely ' . A polyclonal HLA-DR antibody , raised in rabbits and kindly provided by Dr. H. 
Ploegh, The Netherlands Cancer Institute, Amsterdam, together with a MoAb against a 
nonpolymorphic HLA-DR determinant (clone L243, Becton Dickinson) and the CD14 
anti-monocyte/macrophage MoAb WT14 , were applied to cryostat sections, and the 
results were compared with those obtained in the fixed material. 
Biopsy specimens 
Renal allograft biopsies of patients with and without AIR were selected retrospective-
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ly from the pathological and clinical files. Sixteen cases with clinically and histologically 
proven AIR were selected. Criteria for selection were the presence of an interstitial infiltrate 
with tubular invasion consistent with AIR , an increase in WTl4-positive cells in cryostat 
sections with a characteristic peritubular pattern , and a favorable response to antirejection 
therapy. Control cases included 11 renal allograft biopsies without AIR, and with diagno­
ses listed in Table 1. Seven of these control biopsies showed patchy interstitial infiltrates. In 
all cases the core biopsy contained sufficient cortical tissue to allow for counting of cells in 
ten high-power fields. All patients had been treated with CsA, which was replaced by aza-
thioprine and low-dose prednisone 12 weeks after transplantation. The time of biopsy 
varied from 1 to 307 weeks after transplantation. 
Histology and immunohistohgy 
Renal core biopsies of all cases were fixed in Bouin's solution (pH 1.8) for 1 -3 h, except 
for three biopsies (two AIR cases and one control) that had been fixed over the weekend for 
40-48 h. The tissues were embedded in paraffin and 3 μπι sections were routinely stained 
with methenamine silver, periodic acid-Schiff, and chrome aniline blue stain. 
For immunohistology, 3 μιη sections were deparaffmized with xylene for 10 min, fol­
lowed by hydration in ethanol and rinsing in running tap water. Endogenous peroxidase 
activity was inhibited by pretreatment with 3% hydrogen peroxide in phosphate buffered 
saline (PBS) for 30 min. Nonspecific binding sites were blocked by preincubation with 
40% normal swine serum in PBS for 15 min. For staining with KP1, we used the avidin-
biotin technique . A first incubation with KP1 (dilution 1:50), for 60 min, was followed 
by a second incubation with a biotin-conjugated horse anti-mouse immunoglobulin (dilu­
tion 1:100) for 30 min, and a third incubation with the avidin-biotin peroxidase complex 
(Vector Laboratories, USA) for 45 min. An indirect immunoperoxidase procedure was used 
for staining with UCHL1 and L26 , consisting of a first incubation with UCHL1 (dilution 
1:40) and L26 (dilution 1:100) for 60 min, and a second incubation with peroxidase-
labeled rabbit anti-mouse immunoglobulin (dilution 1:80, Dakopatts). For staining of 
paraffin sections with the polyclonal rabbit anti-HLA-DR, a peroxidase-antiperoxidase 
technique was used : incubation of the primary antibody (dilution 1:80) was followed by a 
swine anti-rabbit immunoglobulin (dilution 1:20), and a third incubation with peroxidase-
antiperoxidase complex (dilution 1:800, Dakopatts). Staining of cryostat sections with 
WT14 and the monoclonal and polyclonal antibody against HIA-DR was performed as 
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described previously . Briefly, after a first incubation with specific antibody for 60 min, the 
sections were incubated with peroxidase-labeled rabbit anti-mouse immunoglobulin and 
swine anti-rabbit immunoglobulin respectively. All incubations were carried out at room 
temperature, and each incubation step was followed by washing in PBS. In all procedures 
diaminobenzidine was used as the chromogen and sections were counterstained with hae-
matoxylin for 2 min. 
Scoring of KP1, WT14, and HLA-DRpositivity 
Using an ocular grid divided into 25 fields, we counted the KPl-positive mononuclear 
cells in AIR and in control biopsies in 10 cortical high-power fields (magnification χ 400), 
that were representative for the whole cortical area. Positive cells located in the tubules and 
in the vessels were included in the counts. Glomeruli were not included in the selected 
fields. In frozen sections, the diffusion of the diaminobenzidine product makes counting of 
separate WTl4-positive cells unreliable. Therefore, WT14 positivity in the frozen material 
was expressed semiquantitatively as the extent of peritubular positivity in the section area ' . 
We distinguished five patterns: A) diffuse, over more than 80% of the section area; B) 
patchy, over 50-80% of the section area; C) irregular staining of low density over 20-50% 
of the section area; D) slightly increased staining over less than 20% of the section area; and 
E) dispersed positive cells, as in normal kidneys. HLA-DR staining of the tubular epithe­
lial cells was graded semiquantitatively as positive, weakly positive, or negative, in both rou­
tinely processed and frozen sections. The staining intensities of the peritubular capillaries 
and interstitial cells were used as an internal reference. 
RESULTS 
Two of the 16 cases of AIR were completely negative for KP 1. In the other 14 biopsies, 
KP1 staining was strongly positive in interstitial cells that had the cytological appearance of 
macrophages. In the sections of patients with AIR, these cells were located not only in the 
interstitium but also between TEC, in the tubular lumina, and in the vessels (Figure 1). 
A weaker staining was seen in smaller mononuclear cells, with oval nuclei and a moderate 
amount of clear cytoplasm, consistent with the cytological appearance of small histiocytic 
cells or monocytes. These cells were only present in biopsies with interstitial infiltrates due 
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Figure ΙΑ, В 
KPl staining in a renal allografi with acute interstitial rejection. 
A interstitial increase in KPl-positive celk. Tubular epithelial cells are negative, (x 250); 
В detail, showing the difference in staining intensity between Urge, strongly positive macro­
phages (large arrows) and weakly, stained peritubuUr monocytoid celh (small arrows) 
T: tubule lumen (x 400). 
to AIR and were located directly around the tubular basement membranes, in a pattern simi­
lar to the one we previously observed in cryostat sections using MoAb WT14 (Figure IB). 
In the control biopsies these peritubular cells were not seen. In five AIR biopsies, plasma 
cells and polymorphonuclear granulocytes also showed weak positivity for KPl, but both 
cell types could easily be differentiated from cells of monocyte/macrophage lineage by their 
typical nuclear features. There was a moderate variation in staining intensity between dif­
ferent biopsies. As shown in Table 1, the number of KPl-positive cells was significantly 
higher in AIR than in the controls: 1184 ± 410 per mm" versus 112 ± 126 per mm" (mean 
± SD; p<0.001, Wilcoxon rank sum test). Table 1 also shows the results of the HLA-DR 
staining in serial paraffin sections, and ofWTM staining and HLA-DR staining in the fro­
zen part of the biopsy. Comparison of KPl staining with WT14 staining on cryostat 
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Table 1 
KP1 staining of interstitial monocytes/macrophages in Bouin-fixed renal allograft biopsies with 
acute interstitial rejection and controls. Comparison with staining patterns of polyclonal HLA-DR 
antibody in serial sections, and with monoclonal HLA-DR and WT14 antibody in cryostat sections. 
Histological 
diagnosis 
Acute interstitial 
rejection 
Controls 
CsA nephrotoxicity 
Acute tubular necrosis 
IgA nephropathy 
Membranous nephropathy 
Focal glomerulosclerosis 
Renal artery stenosis 
No pathological changes 
η 
14 
11 
3 
2 
2 
1 
1 
1 
1 
Paraffin sections 
KP1-positive 
cells per mm2 a 
(range) 
1184±410* 
(429-1922) 
112 ±126 
(3 - 367) 
3,172,367 
37,305 
27,46 
16 
27 
51 
175 
HLA-DR 
positivity of 
TEC" 
+ (10) 
±(3) 
-(1) 
+ (D 
±(6) 
-(4) 
-,-,* 
-,± 
±,± 
± 
+ 
-
± 
Corresponding cryostat sections 
HLA-DR 
positivity of 
TECC 
+ (11) 
±(3) 
-(0) 
+ (4) 
±(5) 
-(2) 
±,-,_± 
-,± 
±,+ 
± 
± 
± 
+ 
WT14 
pattern" 
A (14) 
D,NA,B 
D,C 
C,B 
E 
D 
F 
С 
* ρ < 0.001 as compared to controls (Wilcoxon rank sum test) 
a Expressed as mean ± SD for AIR and control groups, and given as individual counts for the 11 control biopsies 
b Expressed as number of biopsies (in parentheses) with positive (+), weakly positive (±), or negative (-) staining with 
polyclonal HLA-DR antibody 
с Expressed as number of biopsies (in parentheses) with positive (+), weakly positive (±), or negative (-) staining with 
monoclonal HLA-DR antibody 
d Extent of peritubular increase in WT14-positive cells expressed as A: diffuse, over more than 80% of the section area; 
B: patchy, over 50-80% of the section area; C: irregular staining of low density over 20-50% of the section area; D; 
slightly increased staining over less than 20% of the section area; E: dispersed positive cells, as in normal kidneys; F: 
inadequate because of necrosis; NA: no frozen tissue available 
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sections of the frozen part of the biopsies is only valid in the control group since, in the AIR 
group, a diffuse increase in WTl4-positive cells (pattern A) had been used as a selection 
criterion. 
Binding of the polyclonal HLA-DR antibody to the HLA-DR antigens on interstitial 
cells, peritubular capillaries and TEC was not abolished by the use of Bouin's solution. A 
variable staining of TEC was found in both rejection cases and controls (Table 1). Ten of 
14 rejection biopsy specimens demonstrated a positive HLA-DR staining, three a weakly 
positive staining, and in one case the staining was completely negative. In the control group, 
TEC was positive for HLA-DR in one biopsy, weakly positive in six specimens, and com­
pletely negative in four others. The staining results of polyclonal anti-HLA-DR in paraffin 
sections were largely comparable with those of monoclonal anti-HLA-DR in the cryostat 
sections (Table 1). 
- UCHL1, generally used for staining Τ cells in formalin-fixed tissues, did not stain the 
Τ cells in our Bouin-fixed material. Similarly, L26 staining was negative in all biopsies, 
except in one case of AIR. 
DISCUSSION 
Our results show that macrophages can be immunohistologically identified with 
MoAb KP1 in routinely processed renal biopsies and that as in our earlier findings using 
MoAb WT14 in frozen material, a significant increase in interstitial macrophages can be 
demonstrated in cases with AIR. 
The moderate variation in staining intensity between different biopsies was probably 
caused by differences in fixation times, since the two biopsies that were completely negative 
proved, in retrospect, to have been fixed in Bouin's solution for 40 and 48 h (over the week­
end). Since a few KP 1-positive cells are always present, even in normal kidneys, a comple­
tely negative KP1 staining can be considered not évaluable. Therefore, both biopsies were 
excluded from the count. One could argue that the deleterious effect of prolonged fixation 
in Bouin's solution could have been prevented by the use of buffered formalin as the routine 
fixative for graft biopsies. The advantage of Bouin's solution, however, is that it gives supe-
rior results for the methenamine silver stain and trichrome stains in particular, which are 
essential for optimal study of glomerular pathology '. Although glomerular lesions are, in 
general, not a hallmark in the diagnosis of AIR, accurate study of the glomerular basement 
membrane is still indicated in renal graft biopsies, not only for the diagnosis of transplant 
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glomerulopathy, but also in cases of recurrence of the original renal disease in the graft and 
for de novo-developing glomerular diseases . Optimal visualization of the glomerular base­
ment membrane in the paraffin sections is even more essential in cases in which no frozen 
tissue is available for immunofluorescence. For these reasons, and for the practical reason 
that we prefer a uniform fixation method for graft biopsies and non-graft biopsies, we have 
thus far routinely used Bouin's solution for renal tissue in our laboratory. After our findings 
with KP1 in the Bouin-fixed material, we compared the results with those of histological 
and immunohistological stainings in a small series of graft biopsies fixed in buffered for­
malin. To our surprise, the KP1 staining in formalin-fixed tissue was not better, and speci­
fically not more intense, than that in the Bouin-fixed material with a normal (1-3 h) fixa­
tion time. The staining of TEC with polyclonal anti-HLA-DR was, in general, more intense 
in the formalin-fixed biopsies, whereas the staining with methenamine silver and trichrome 
were, as expected, less satisfactory. 
As shown in Table 1, there was a good correlation between a low extent of WT14 
staining (patterns D and E) and low numbers of KP 1-positive cells. In the WT14 catego­
ries В and C, both low and high numbers of KP 1-positive cells were found. For WT14 cate­
gory C, such a variation can be expected. However, in WT14 category B, with a high extent 
of WT14 positivi ty, the finding of a low number of KP 1-positive cells, as in one of our con­
trol cases (Table 1), is unexpected. The cryostat section of this biopsy showed, apart from a 
few patchy infiltrates, a peritubular increase in WTl4-positive cells in 60% of the tissue 
area. In this case the discrepancy between WT14 and KP1 staining could be due to sampling 
error, but loss of antigenic structures seems more likely since this biopsy had been fixed in 
Bouin's solution over the weekend. The HLA-DR expression on tubular epithelial cells was 
found to be weakly positive in the paraffin section, whereas it was scored as positive in the 
parallel cryostat section, which is also an argument for loss of antigenicity due to prolonged 
Bouin's solution. 
Obviously, apart from the different scoring systems used for quantitation of KP1 and 
WT14 staining, the number of control biopsies is too low to allow for statistical comparison 
of the results between or within the subgroups. Moreover, the number of biopsies, in both 
the AIR group and control groups, is not sufficient to recommend routine use of the num­
ber of KP 1-positive cells as a quantitative indication of the probability or severity of AIR. 
Apart from this, the time-consuming procedure of counting cells per mm is not feasible 
for routine diagnosis. We have used the counting of KP 1-positive cells as a means of illustra­
ting a quantitative increase in interstitial monocytes/macrophages in cases of AIR and to 
test whether KP1 staining may be helpful in cases in which frozen tissue is not available or 
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not representative. When a frozen fragment of renal cortex is available, WT14 staining is 
preferable: the sections can be cut immediately, the staining is easy to perform, and the 
extent of positivity, graded as patterns A to E as previously published, can be estimated in 
a few seconds. Another disadvantage of KP1 staining is that the peritubular localization of 
the macrophages, which is so characteristic of WT14 staining in frozen sections of biopsies 
with AIR ' , is not very prominent in the paraffin sections. This is due to the relatively weak 
staining intensity of the monocytoid cells that are located direcdy around the tubular base-
ment membranes (Figure IB). In cases in which these weakly staining cells are not obser-
ved, it may be difficult or impossible to differentiate the interstitial increase in macropha-
ges from an increase due to interstitial inflammation other than AIR. A MoAb like WT14, 
with a high affinity for these monocytoid cells, would be preferable, but thus far we have 
not found a CD 14 antibody that gives a satisfactory staining in routinely fixed tissue. In 
frozen sections, KP1 staining resulted in a stronger positivity of monocyte/macrophages 
than in paraffin sections, but was accompanied with a variable and sometimes considerable 
background staining that obscured the peritubular pattern present in serial sections stained 
with WT14. For similar reasons, staining of frozen sections with the polyclonal HLA-DR 
antibody had no advantage over staining with the monoclonal antibody. 
The variability in HLA-DR staining of TEC in rejection cases and controls (Table 1) 
is in accordance with our previous findings in cryostat sections and with the results of other 
studies . Since these variable results were also seen in the parallel frozen sections (Table 1), 
a fixation artefact as cause for this variation seems unlikely. In paraffin sections the staining 
results with the polyclonal antibody were, both in Bouin's solution and in formalin-fixed 
material, less intense than those obtained with the monoclonal HIA-DR antibody in cry-
ostat sections. Still, since grading was performed with the use of internal controls, the blind-
ly scored, semiquantitative scales corresponded fairly well with those in the frozen sections 
(Table 1). 
The absence of positive staining of the infiltrates in AIR with UCHL1 and L26 is pro-
bably due to the low pH of Bouin's solution, since the staining was positive in the forma-
lin-fixed biopsies. 
In conclusion, we found that MoAb KP1 can be used for staining of mononuclear cells 
of monocyte/macrophage lineage in routinely processed renal allograft biopsies, even after 
Bouin's solution, provided fixation times are kept within the recommended limits of 1-3 h. 
Staining of routinely fixed allograft biopsies with KP 1 can thus serve as an adjunct in the 
diagnosis of AIR, especially in cases for which frozen material is not available for staining 
with anti-CD 14 MoAb. 
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ABSTRACT 
Previously, we demonstrated that in acute interstitial rejection, immunohistological 
staining of renal allograft biopsies with the CD 14 monoclonal antibody (MoAb) WT14, 
reacting with human monocytes/macrophages, shows a characteristic peritubular increase 
of positive cells. To test the diagnostic value of this CD 14 positivity, we compared, in 154 
unselected renal allograft biopsies, the extent of peritubular WT14 staining with a) the ori-
ginal histological diagnosis, made with knowledge of clinical data; b) the retrospectively and 
blindly scored histological diagnosis according to the criteria of the Banff classification; and 
c) the eventual clinical diagnosis, which included evaluation of the response to therapy. The 
extent of peritubular WT14 positivity, blindly scored on cryostat sections of the frozen part 
of the biopsies, correlated positively with the probability of acute rejection (AR). When 
using a cutoff of 70% WT14 positivity for the diagnosis of AR, as extracted from a recei-
ver operating characteristic curve, the WT14 diagnosis had a positive predictive value of 
9 1 % and a negative predictive value of 56%, compared with the original histological diagno-
sis. Compared with the Banff diagnosis of AR (grade I-III), these values were 95% and 
47%, and compared with the clinical diagnosis, 84% and 63%, respectively. The WT14 
diagnosis essentially corrected the original histological diagnosis in 7 cases, and was consis-
tent with the eventual diagnosis in 5 equivocal cases. We conclude that the extent of peri-
tubular CD 14 positivity can be used as a marker for AR and can serve as a valuable addi-
tional criterion for AR in the histological examination of renal allograft biopsies. 
INTRODUCTION 
After renal transplantation, early diagnosis and adequate treatment of acute rejection 
(AR) are essential to restore and maintain renal graft function. In some cases, the clinical 
symptoms unequivocally point to rejection, thus allowing the clinician to institute antire-
jection therapy without histological confirmation. More often the clinical signs are not spe-
cific for rejection and have to be differentiated from other causes of declining graft func-
tion, such as acute tubular necrosis (ATN), Cyclosporine (CsA) nephrotoxicity, infection, 
surgical complications, or a combination of multiple factors. In such cases, as well as in 
cases that do not allow for a clear-cut answer to the question of rejection or no rejection, a 
core biopsy is taken, and the consultant pathologist is expected to make a decisive diagno-
sis . Since, especially in the absence of intimai arteritis, the histological diagnosis of AR 
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heavily depends on the presence of interstitial leukocytic infiltration, major problems in the 
diagnosis can be expected in cases in which interstitial infiltration is due to other causes, 
such as urological obstruction with bacterial infection, viral infection, or drug hypersensi-
tivity, while histological interpretation is further complicated by the fact that interstitial 
infiltrates may occur in normally functioning grafts " . Therefore, many investigators have 
searched for additional histological and immunohistological markers of AR that may 
improve the reliability of the histological diagnosis " . Immunohistological staining of 
tubular epithelial cells (TEC) with anti-HLA-DR antibody and immunohistological ana-
lysis of the lymphocytic infiltrate have not fulfilled their original promise as useful markers 
for AR, since neither increased HLA-DR expression of TEC nor predominance of CD8 
lymphocytes in the infiltrates is sufficiently specific "' . Our earlier demonstration of a 
characteristic peritubular increase of macrophages in acute renal allograft rejection, demon-
strated with WT14 (CD 14) staining, was a new, promising finding with regard to its pos-
sible use as a rejection marker". Recently, a significant increase of CDl4-positive cells in 
rejection of liver allografts and cardiac allografts has been reported. For the validation of 
WT14 (CD14) staining of peritubular macrophages as an independent marker for renal 
allograft rejection, we determined the sensitivity, specificity, and predictive values of blind-
ly scored results in unselected biopsies, in relation to standardized histological and clinical 
diagnoses. 
MATERIALS AND METHODS 
Parients and alfagrafi biopsies 
From January 1,1988, until December 31,1989, a total of 223 consecutive renal graft 
biopsies were performed in 149 renal transplant recipients. Indications for percutaneous 
renal core biopsy were oliguria persisting for more than 10 days after transplantation, dete-
riorating renal graft function, or proteinuria. Sixty-nine biopsies were excluded from our 
comparative study because of inadequacy of either the frozen (n=30) or the fixed (n=39) 
part of the tissue specimen. The remaining 154 biopsies originated from 116 grafts in 114 
patients. In these patients, the interval between histological examination and transplanta-
tion varied from 1 to 730 weeks, with a mean interval of 42 weeks. In 33 patients, more 
than 1 biopsy from the same graft was taken, with a time interval of 2-81 weeks (mean 11 
weeks). The immunosuppressive regimen in the patient group undergoing transplantation 
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before 1985 (n=10) consisted of azathioprine (Aza) and prednisone. From 1985 on, all 
patients were initially treated with CsA and prednisone, followed by conversion to Aza and 
prednisone at 12 weeks after transplantation" . Ten patients, transplanted in 1988, were ini­
tially treated with Aza and prednisone in combination with a 10-day course of the anti-
CD3 MoAb WT32 i 6 . 
Antibody WT14 
The CD14 MoAb "WT14, developed in our laboratory as described previously , is a 
murine IgGl antibody that binds to membranous antigens of human monocytes and 
macrophages, but not to В or Τ lymphocytes, or granulocytes. In tissue sections WT14 
reacts with intravascular monocytes, histiocytes, tissue macrophages, and both weakly and 
variably with endothelial cells of medium-sized and small blood vessels. In cryostat sections 
the staining has a diffuse cytoplasmic appearance with a rim of increased intensity at the 
periphery of the cell, but immunoelectron microscopy confirms the membranous localiza­
tion of the antibody (Figure 1). 
Histohgy and immunohistohgy 
A representative portion of the graft biopsy was fixed in Bouin's solution, and a smal­
ler part was snap frozen in liquid nitrogen. In selected cases, a third part of the biopsy was 
fixed in buffered glutaraldehyde for electron microscopy. For routine histological examina­
tion, 2 μπι paraffin sections of the Bouin-fixed tissue were stained with haematoxylin and 
eosin, periodic acid-Schiff, silver methenamine, and chrome aniline blue. The total num­
ber of tissue cross-sections examined was higher than 50 per biopsy. For immunohistology, 
4 μπι cryostat sections of the fresh-frozen part of the biopsy were stained with WT14 (undi­
luted supernatant of culture medium), and anti-HLA-DR (clone L243, dilution 1:100, 
Becton Dickinson, Mountain View, CA) in a standard, indirect immunoperoxidase techni­
que as described earlier, using diaminobenzidine (0.5 mg/ml) as chromogen . Since graft 
biopsies are never completely negative for WTl4-positive or HLA-DR-positive cells, sepa­
rate positive and negative staining controls were unnecessary. The cortical origin of the fro­
zen part of the graft biopsy was assessed by a periodic acid-Schiff stain, in which at least 
1 glomerulus had to be present. 
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Figure 1 
Immunoekctron micrograph ofWTl 4-positive cells in a renal allograft biopsy with AR. Positive 
staining can be seen along the cell border of intravascuhr and interstitial celh of 
monocyte/macrophage origin (arrows). Endothelial cells may be weakly positive (arrow-heads) 
(original magnification χ 1400), Τ: tubule. 
For the demonstration of WT14 staining in immunoelectron microscopy, small frag­
ments of a rejected renal grah were immersed in periodate-lysine 2% paraformaldehyde 
fixative for 2.5 h, cryoprotected in 2.3 M sucrose for 45 min, and snap frozen in liquid 
nitrogen. Thick (25 μιτι) cryostat sections were incubated overnight with WT14 at 4°C, fol­
lowed by incubation with peroxidase-labelled rabbit anti-mouse (Dakopatts, Glostrup, 
Denmark), diluted 1:20 in PBS-1% BSA for 90 min, and, after washing, stained with 
diaminobenzidine (0.05%) in PBS and 0.03% Η,Ο, as chromogen. After washing in tap 
water of 4°C for 18 h, the slides were dehydrated and embedded in epon. Ultrathin sections 
(90 nm) were prepared on a Reichert Ultramicrotome, and examined unstained in a Jeol 
1200 EX electron microscope. 
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Scoring ofWTlé and HLA-DR staining 
The cytoplasmic staining pattern of CD14-poskive cells in cryostat sections, with 
nonrecognizable cell borders in the peritubular accumulations of these cells, makes it 
impossible to compare exact numbers of counted cells. Moreover, quantitative cell counting 
is not a technique that can be used for routine histological diagnosis. Therefore, the extent 
of WT14 positivity was estimated as the percentage of positive peritubular staining in rela-
tion to the total cortical peritubular area in the section. WT14 scores were assessed in a blin-
ded way, without knowledge of clinical data or histological findings, and given in semi-
quantitative categories, covering a scale of 0-100%. Examples of staining results and 
corresponding scores are illustrated in Figure 2. 
The HLA-DR staining of TEC was scored as positive when an increased expression to 
at least a moderate degree was seen , with use of the staining intensities of the peritubular 
capillaries and interstitial cells as internal references. In 3 cases HLA-DR staining was not 
available. 
Histobgical and clinical diagnoses 
For comparison of the WT14 scores with the histological and clinical diagnoses, we 
divided these diagnoses in categories indicating the probability of AR. The original histo-
logical diagnoses, made by one of us (K.J.M.A.) with knowledge of clinical data, were 
extracted from the pathological files and categorized in 4 groups: 1) Histological signs of 
AR; in general, this diagnosis was based on the presence of edema, an interstitial infiltrate 
with tubulitis, and intimai arteritis; two cases with intimai arteritis and interstitial edema 
but only a minimal interstitial infiltrate were included in this category; 2) Chronic rejec-
tion without a significant interstitial infiltrate; 3) Equivocal diagnosis with regard to AR; 
and 4) No rejection. 
The histological diagnoses according to the criteria of the recently proposed Banff clas-
sification were retrospectively and blindly scored (M.J.J.T.B.), without knowledge of 
either patient data or immunohistology. The Banff diagnoses were categorized in 4 groups: 
1) Acute rejection grades I—III, including intimai arteritis; 2) Borderline changes; 3) 
Chronic rejection; and 4) No rejection. 
The definitive clinical diagnoses were made retrospectively by 3 experienced nephro-
logists (I.M.M.D., A.J.H., R.A.P.K.) based on clinical data, original histological diagnosis, 
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Figure 2 
Two examples of scoring of immunohistological staining of cryostat sections of renal grafi biopsies 
with WT14: 
A acute interstitial rejection with positivity over 90-100% of the peritubular area; 
В chronic vascuUr rejection with WT14 positivity over 30-39% of the peritubular area 
(original magnification χ 250). 
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and the response to treatment. These clinical diagnoses were, after formulation of a con-
sensus diagnosis, categorized in 5 groups: 1) Acute rejection with a favorable response to 
antirejection therapy; 2) Probable rejection with incomplete or no response to therapy; 
3) Chronic rejection with proteinuria and gradual loss of renal function; 4) Uncertain 
diagnosis; and 5) No rejection. The latter category included CsA nephrotoxicity, postrenal 
obstruction, vascular occlusion, ATN, and other changes not due to rejection. 
Evaluation of the WT14 staining as a diagnostic test 
For calculation of the sensitivity and specificity of the WT14 staining as a diagnostic 
test, and the positive and negative predictive values, the optimal cutoffs for evaluation of 
the WT14 scores as true positive and true negative were determined from a receiver opera-
ting characteristic (ROC) curve, graphically drawn according to the method described by 
Sackett et al. For this purpose we used the blindly scored histological diagnoses according 
to the Banff working classification as the standard reference diagnosis, and related these 
with WT14 scores in first-graft biopsies only (116 grafts in 114 patients) to avoid possible 
influences of already-given therapy. After determination of the optimal cutoffs, the sensiti-
vity, specificity, and positive and negative predictive values of the WT14 staining were cal-
culated for the whole group of 154 biopsies, and for the groups of first biopsies and 
second/third biopsies separately. 
RESULTS 
The correlations between the extent of peritubular WT14 positivity in the cryostat 
sections and the categories of the original histological diagnosis and the objectively scored 
Banff diagnoses are illustrated in Figures 3 and 4, respectively. Comparison of the WT14 
score with the clinical diagnoses, as given in Figure 5, shows a similar pattern. It is evident 
from all three figures that with increasing WT14 scores, there is an increasing probability 
of rejection. 
The use of the gradual scaling system for the extent of WT14 positivity enabled us to 
determine the optimal cutoff for interpretation of the WT14 staining by plotting our data 
in an ROC Curve , i.e., a graph of pairs of true-positive rates (sensitivity) and false-posi-
tive rates (100% - specificity) corresponding with each possible cutoff for the WT14 score 
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Figure 3 
Original hutobgical diagnoses and corresponding WT14 scores (percentage oftubukr area with 
peritubuhr WT14positivity). The numbers of biopsies in each category are given above the bars. 
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Figure 4 
Blindly scored histological diagnoses according to the criteria of the Banff classification and cor­
responding WT14 scores (percentage oftubukr area with peritubuhr WT14 positivity). The 
numbers of biopsies in each category are given above the bars. 
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Figure 5 
Definitive clinical diagnoses and corresponding WT14 scores (percentage of tubular area with 
peritubufór WT14 positivity). The numbers of biopsies in each category are given above the bars. 
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Figure 6 
ROC curve comparing WT14 diagnosis and histological diagnosis according to the Banff criteria, 
determined for the given cutoffs. 
in combination with the histological diagnosis. The ROC curve, in which WT14 scores of 
the 116 first biopsies are related with the Banff diagnoses, is drawn in Figure 6. The false-
positive rates for cutoffs of 60%, 70%, and 80% "WT14 positivity are 9%, 6%, and 6%, 
respectively, whereas the sensitivities for the respective cutoffs are 70%, 63%, and 50%, 
respectively. Taking into account that a false-positive diagnosis may lead to an unnecessary 
and potentially harmful antirejection treatment, we decided that the optimal cutoff for 
interpretation of the WT14 staining results is a positivity of 70% of the section area. By a 
similar procedure, we determined the optimal cutoff for the diagnosis of no rejection, also 
in comparison with the Banff diagnosis in first biopsies; for this purpose we considered ali 
diagnoses other than AR grade I-III as no rejection. By this procedure, the optimal cutoff, 
extracted from the ROC curve for the diagnosis no rejection, was at 40% (curve not 
shown). 
Seventy-five of 82 cases with >70% WT14 positivity had an original histological 
diagnosis of AR (91%), and 78 had a Banff diagnosis of AR (95%). Of the 82 cases, 
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69 (84%) also had a clinical diagnosis of AR with a favorable response to therapy. When 
using the extent of 40% WT14 positivity as the maximal cutoff for the diagnosis no rejec-
tion, the WT14 diagnosis correctly diagnosed 29/44 (66%) cases as no rejection when com-
pared with the original histological diagnosis. Compared with the final clinical diagnosis, 
the cutoff of 40% correctly diagnosed 34 of 58 (59%) cases with no rejection (including 
cases with diagnoses of uncertain and chronic rejection). The sensitivity, specificity, and 
predictive values of the WT14 diagnoses in correlation with histological and clinical diag-
noses are given in Table 1. 
Since the ROC curves were drawn on data of first biopsies only, we tested the chosen 
cutoffs separately in the remaining group of 28 second and 5 third biopsies. In this group, 
28 had a WT14 score >70%, which corresponded with the original histological diagnosis 
of AR in 24 (86%) and with the clinical diagnosis in 24 cases (86%). For first biopsies only, 
these correlations were 82% and 9 1 % respectively. 
To answer the question of whether the extent of WT14 staining can serve as decisive 
information in individual cases, we list, in Table 2, the cases with major discrepancies 
between WT14 score and histological and/or clinical diagnoses, combined with informa-
tion about instituted therapy and clinical response. 
Fake-positive WT14 scores 
In cases 1-11, the WT14 score was high (>70%), in contrast with the eventual clini-
cal or histological diagnosis, or both. In cases 1-5, the original histological diagnosis was 
AR, and in 10 of the 11 cases, the Banff diagnosis was AR. Antirejection treatment, with 
simultaneous discontinuation of CsA or other treatment such as drainage for obstruction 
was given in 8 of 11 cases, with a favorable reaction in all but one (case 11). Although the 
final clinical evaluation led to the diagnosis no rejection in 8 of these cases, a rejection com-
ponent as the cause of graft dysfunction cannot be excluded. Case 8, with an initial WT14 
score of 85%, received antithymocyte globulin on clinical grounds before the histological 
diagnosis was known. Treatment was discontinued when the histology was equivocal and 
the clinical diagnosis was changed to ATN. After an initial gradual increase in renal func-
tion, the patient again developed clinical AR 2 weeks later, with WT14 score of 95% (listed 
as case 9). 
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Table 2 
Aberrant WT14 scores' in view of histological and/or final clinical diagnoses, with given treatment and 
response. 
Case 
1 
2 
3 
4 
5 
6 
7 
8" 
9h 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
WT14 
score" 
95 
75 
85 
75 
85 
75 
85 
85 
95 
75 
95 
25 
15 
25 
35 
5 
15 
15 
15 
15 
35 
35 
25 
35 
35 
25 
Original 
histological 
diagnosis" 
AR 
AR 
AR 
AR 
AR 
Equivocal 
Equivocal 
Equivocal 
No AR 
No AR 
No AR 
equivocal 
equivocal 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
Banff 
diagnosis" 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
No AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
Chronic 
rejection 
Acute and 
chronic 
rejection 
Therapy 
Conversion CsA to Aza 
Conversion CsA to Aza/ATG' 
Methylprednisolone i.v. 
Prednlsone/ATG 
Methylprednisolone i.v. 
/ATG/drainage 
Switch Aza + WT32 to CsA 
ATG/conversion CsA to Aza 
Two doses ATG 
Prednisone/ATG 
None 
Dilatation renal artery stenosis/ 
conversion CsA to Aza/prednisone 
Dilatation renal artery stenosis 
None 
None 
Prednisone/conversion CsA to Aza 
Drainage/prednisone 
Drainage/prednisone 
Prednisone 
Prednisone 
Prednisone 
ATG 
ATG 
ATG 
WT32 
Prednisone 
Prednisone 
Clinical 
response' 
F 
F 
F 
F 
F 
F 
F 
F 
F 
U 
U 
F 
F 
F 
F 
F 
F 
F 
F 
F 
U 
F 
F 
U 
F 
F 
Clinical diagnosis 
ι 
CsA nephrotoxicity 
CsA nephrotoxicity0 
ATN' 
ATN' 
Postrenal obstruction9 
Uncertain0 
Uncertain' 
ATN' 
AR 
Chronic rejection 
No rejection9 
No rejection 
No rejection 
No rejection 
CsA nephrotoxicity 
Postrenal obstruction 
Postrenal obstruction 
Probable rejection 
AR 
AR 
AR 
AR 
AR 
AR 
Probable rejection 
Probable rejection 
Footnotes to Table 2 
a AberrantWTt4 scores: WT14 score ¿70% with clinical and/or histological diagnosis no rejection (cases 1-11) or WT14 score <40% 
with histological and/or clinical diagnosis AR (cases 12-26). 
b The WT14 score, estimated as the percentage of positive peritubular staining of the total peritubular area in the cryostat section of the 
frozen part of the biopsy, Is given as the mean value within the corresponding category (i.e., 35 means WT14 score 30-39% positivity). 
с The original histological diagnoses, made with knowledge of clinical data on the fixed part of the biopsy, were retrospectively divided 
into 4 categories, indicating the histological probability of AR. 
d These histological diagnoses were made retrospectively, without knowledge of the clinical data, according to the criteria of the Banff 
classification27 (AR grades Mil), 
e F = favorable outcome; U = unfavorable outcome, indicating graft loss and/or return to dialysis, 
f ATG = Antithymocyte globulin, 
g Although the final clinical diagnosis was scored as no rejection or uncertain, a rejection component as cause of the graft dysfunction 
could not be excluded, 
h Biopsies 8 and 9 were taken from the same graft, with an interval of 2 weeks. 
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Fake-negative WT14 scores 
In cases 12-26 (Table 2), the WT14 score was low (<40%) in contrast with one or both 
histological diagnoses of AR. In 6 cases (numbers 12-17), this score was correct in view of 
the clinical outcome. In 9 cases (numbers 18-26), a low WT14 score <40% was inconsis-
tent with one or both histological diagnoses and, in some of the cases, also with the clini-
cal one. Of these, case 18 had an occlusion of the iliac artery, proximal of the anastomosis 
with the graft artery, that was treated surgically. The biopsy, taken during this surgery at 6 
days after starting antirejection therapy, demonstrated intimai arteritis with edema. Case 19 
was still receiving antirejection therapy for a histologically proven AR 5 weeks earlier, while 
developing a second rejection episode, and case 24 had finished an oral prednisone course 
8 days before. Like case 18, case 24 showed severe interstitial edema with only minimal 
infiltrate. Cases 25 and 26 combined histological signs of chronic rejection with a mild and 
a moderate infiltrate, respectively. Both patients clinically showed no improvement of renal 
function after an oral prednisone course, although serum creatinine stabilized at a higher 
level, and they were clinically scored as probable rejection. In the remaining 4 cases (20-23), 
the low WT14 score cannot be explained other than by sampling error. 
Comparison of HLA-DR staining of TEC with the Banff histological diagnoses 
showed that in 108 of 113 cases with AR, tubular HLA-DR expression was increased, while 
in the group with a Banff diagnosis no rejection HLA-DR staining was scored as positive 
in 36 of 38 cases. This results in a sensitivity of increased HLA-DR staining of TEC as a 
marker for rejection of 96%, a specificity of 5%, with a predictive value of 75% for a posi-
tive test and 29% for a negative one. In comparison with the original histological diagno-
ses and the clinical diagnoses, the respective values were in the same range. 
DISCUSSION 
Our results show that in renal allograft biopsies the extent of peritubular macrophage 
infiltration is directly related to the probability of AR, and can be used as an additional cri-
terion in histologically difficult cases. A "WT14 positivity of >70% can be considered con-
sistent with rejection, and a score of <40% as evidence of involvement of other causes of 
graft failure. The method of indirect immunoperoxidase staining of frozen sections is easy 
and quick, a standard procedure in every pathology laboratory, and, if necessary, available 
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within 4-5 h. The extent of peritubular WT14 or CD14 positivity, visible as a rim of posi-
tivity around the tubuli, can be easily read from the sections without special training. 
A periodic acid-Schiff stain of the cryostat sections is advisable to assess the corneal origin 
of the frozen part of the biopsy, since the subcortical renal tissue shows a dispersed staining 
pattern of WTl4-positive cells both in normal kidneys and in AR. 
Unlike our earlier division of WT14 scores in the more or less randomly chosen cate-
gories of <20% positivity, 20-50%, 50-80%, and >80%, respectively", we now used a gra-
dual scale, which allowed us to determine the point at which the extent of WT14 positivi-
ty correlated best with AR or no AR. The choice of the cutoffs 40% and 70% WT14 
positivity for a negative and positive diagnosis, respectively, indicates that the categories 40-
70% will give no decisive information with regard to rejection in individual cases. In our 
series, the total number of biopsies in these categories was 28, i.e., 18.2%. Since the evalu-
ations of the diagnostic values of WT14 scores in second/third biopsies are not essentially 
different from those in the group of first biopsies, we conclude that the chosen cutoffs of 
WT14 positivity give equally valuable information in repeated biopsies, provided that, as 
in the interpretation of routine sections, recently given antirejection treatment is taken into 
account. 
The inconsistencies between WT14 scores 40-60% and the original histological 
diagnoses in Figure 3 are not seen in Figure 4, wherein WT14 scores are compared with the 
blindly scored diagnoses according to the Banff criteria. This may indicate that knowledge 
of the clinical diagnosis may interfere with objective interpretation based on purely histo-
logic criteria. The resemblances between Figures 3 and 5, especially in the inconsistent 40-
60% WT14 scores, can be explained by the fact that the original diagnosis was based on 
both clinical and histological findings, while in turn this histological diagnosis was part of 
the criteria leading to the eventual clinical diagnosis. As can be expected, the biopsies with 
40-60% WT14 scores include most of the cases with moderate or patchy infiltrates and 
cases in which the declining function is due to a complex combination of rejection with 
other factors. Of the 10 patients (6.5%) in these categories who had a histological diagno-
sis of AR, 7 cases showed only patchy infiltrates, and one of these patients had been treated 
with methylprednisolone 1 day before the biopsy was taken. The other 3 biopsies, also 
diagnosed as AR, showed severe interstitial edema, with a less prominent interstitial infil-
trate, resulting in a low WT14 score (discussed below). From the comparison of Figures 3, 
4, and 5, and from the listed Banff diagnoses in Table 2, we conclude that the Banff crite-
ria lead to a more sensitive but less specific diagnosis of AR in difficult cases, with risk of 
overdiagnosis as illustrated by cases 12 and 13. Consistent with the advice of Solez et al., 
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Figure 4 also indicates that borderline changes should not be diagnosed as AR. Further eva­
luation of the Banff schema is in progress in several centers. 
As in our earlier study' , we also saw in this series 6 cases that combined a minimal 
interstitial infiltrate with a high WT14 score, caused by a narrow rim of positive staining 
around rather closely packed tubuli over a large part of the section area. An example of this 
was case 9 in Table 2, which combined histological ATN with a focal and mild interstitial 
infiltrate, a WT14 score of 95%, clinical AR, and a good response to therapy, which star­
ted on clinical diagnosis. Apparently, in this case, the infiltration with CDl4-positive cells 
preceded the development of a substantial lymphocytic infiltrate. This illustrates that the 
infiltration with macrophages is an early event in the process of rejection, and not a late and 
prognostically unfavorable sign, as has been concluded earlier from studies in suspensions 
and in biopsies of rejected renal grafts " " . 
The increase of macrophages in rejecting grafts has been reported by several authors 
* ', but the role of these cells has received considerably less attention than that of Τ cells. 
Theoretically, macrophages may be involved at different stages of the process that leads to 
graft damage. By production of monokines and interaction with Τ cells, activated macro­
phages may be important mediators in the development and amplification of the inflam­
matory response. In the actual destruction of the graft cells, macrophages can act as effec­
tor cells, by production of cytolytic enzymes, O, radicals, and nitric oxide metabolites , 
and also by a more direct cytotoxic action, either in an antigen-dependent mechanism 
(ADCC) or, as was suggested by MacPherson and Christmas , by a direct cell-cell contact. 
The assumption that macrophages merely function as phagocytic cells, involved in the 
clearance of necrotic cell components in the later phases" , is not compatible with their early 
appearance in the graft, even at stages in which the interstitial infiltrate is barely visible by 
light microscopy. In heart allografts in rats, MacPherson and Christmas33 found accumula­
tion of macrophages from day 3, increasing to numbers more than twice that of lympho­
cytes by day 5-7. These macrophages seemed to be stretched along the myocardial cells, 
comparable to our finding of a linear localization around the tubular borders. In view of the 
fact that the peritubular localization of the CDl4-positive cells is highly characteristic for 
acute interstitial rejection, one might expect that the results of the WT14 staining would 
directly reflect the presence and extent of an AR component, with an even higher sensitivi­
ty and specificity than we actually found. Several factors prevent such a clear-cut correla­
tion. First, the presence of an interstitial infiltrate does not necessarily mean that there is an 
ongoing process of AR, necessitating antirejection therapy . A second factor, interfering 
with accurate diagnosis, is the well-known risk of sampling error, inherent to the method 
65 
of diagnosis by core biopsy . In about 25% of the biopsies, infiltrates due to rejection are 
patchy " , while medium-sized arteries are not present in all biopsies. A third problem, also 
evident in our series, is that cases of acute or chronic rejection may show severe interstitial 
edema as a predominant feature, with comparatively little interstitial infiltrate . In such 
cases, the general picture, combined with clinical data and/or signs of intimai arteritis, will 
usually lead to a correct histological diagnosis, but the WT14 score may be relatively low. 
Examples of this were cases 18 and 24 in Table 2. Since the edema is prominent in the rou-
tine sections, and usually also visible in the frozen sections, this pitfall is easy to avoid. 
Finally, the most important problem, involving all tests dealing with the diagnosis of rejec-
tion, is due to the inherent limitations of the criteria for the histological and clinical diagno-
ses. These criteria strongly need additional parameters, but they are nevertheless used as the 
gold standard. 
In conclusion, we have demonstrated that the peritubular increase of CDl4-positive 
cells is a characteristic event in AR of renal allografts and that the extent of positive staining 
can be used as a matker for the diagnosis. Although limitations inherent to the biopsy pro-
cedure are to be kept in mind, immunohistological staining with WT14 provides a useful 
and welcome additional parameter for rejection that gives valuable information in equivocal 
and complex cases, and should be used as a an easy and quick routine procedure in combi-
nation with conventional histology. 
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INTRODUCTION 
A histological diagnosis of renal allograft rejection can be made readily if the clear-cut 
picture is present (i.e., considerable interstitial infiltrate, tubular invasion, and intimai arte­
ritis ). In many cases, however, the histological changes are less characteristic and the diffe­
rential diagnosis, especially with regard to Cyclosporine (CsA) toxicity, borderline changes, 
and innocent interstitial infiltrates, may be difficult and subject to variable interpretation *. 
Recently, the Banff working classification of kidney transplant pathology was proposed as 
an attempt to devise a schema for interpretation and gradation of the histological findings 
in renal graft biopsies that can be used as an indication for therapeutic consequences and 
expected graft survival . In the Banff schema, apart from interstitial infiltration, tubulitis 
and intimai arteritis are important lesions indicative of acute rejection (AR). As stated by 
the authors, the usefulness of the Banff schema with regard to standardization of histologi­
cal criteria for rejection and clinical implications must be assessed by clinicopathological 
studies in larger series . We tested the value of the Banff criteria by comparing the retro­
spectively and blindly scored histological diagnosis according to the Banff classification 
with the eventual clinical diagnosis. 
MATERIALS AND METHODS 
The clinical analysis was done in a series of 246 consecutive renal allograft biopsies 
over a period of 3 years (1988-1990). Indications for biopsy were graft dysfunction with an 
increase of creatinine > 25% and/or proteinuria > 2.5 g/24 h. The immunosuppressive regi­
men consisted of CsA and prednisone. CsA was started at a dose of 12 mg/kg and was 
tapered down to 5 mg/kg in the 12 weeks following transplantation, with conversion to 
azathioprine in a dose of 3 mg/kg at 12 weeks after transplantation. Prednisone was started 
at a dose of 100 mg daily, with a gradual decrease to 25 mg daily during the first month, 20 
mg during the second and third month, and then 10 mg. Core biopsies were performed 
using a 14-gauge Tru-cut needle. Histological examination was performed retrospectively, 
without knowledge of clinical data, on 2 ц т paraffin sections of Bouin-fixed renal tissue 
stained with haematoxylin and eosin, periodic acid-Schiff, silver methenamine, and chrome 
aniline blue. Biopsies with insufficient cortical tissue were excluded as inadequate. The his­
tological findings were, according to the Banff schema, grouped in six categories: 
1) Normal; 2) Hyperacute rejection; 3) Borderline changes ("very mild AR"); 4) AR, 
71 
divided into grade I: miid AR, grade II: moderate AR, and grade III: severe AR; 5) Chronic 
allograft nephropathy (CR), grade I to III, and 6) Other changes including CsA toxicity and 
acute tubular necrosis (ATN)'. 
The final clinical diagnoses were made retrospectively by three nephrologists based on 
clinical signs, original histological diagnosis, response to therapy, and eventual outcome. 
These clinical diagnoses were coded as: 1) AR; 2) Probable AR; 3) Equivocal, or uncertain 
rejection combined with other causes of graft dysfunction; 4) Chronic rejection (CR); and 
5) No rejection (no R). 
RESULTS AND DISCUSSION 
Of a total of 246 consecutive renal allograft biopsies, 210 (originating from 145 
patients) were adequate and available for analysis. The time interval between biopsy and 
transplantation varied from 1 to 308 weeks (mean 24 weeks). The clinical diagnoses in each 
Banff category are summarized in Table 1. There were no biopsies with normal histology or 
with signs of hyperacute rejection. 
Table 1 
Comparison of the final clinical diagnosis and the Banff histological diagnosis in 210 renal graft 
biopsies. 
BANFF diagnosis 
Borderline changes 
AR Grade I 
Grade U/H! 
CR/CsA/ATN/other 
Total 
No. of Bx 
38 
30 
118 
24 
210 
AR 
8 
14 
85 
1 
108 
prob. 
6 
2 
13 
1 
22 
Clinical diagnosis 
AR Equivocal 
0 
2 
7 
0 
9 
CR 
8 
2 
5 
9 
24 
noR 
16 
10 
8 
13 
47 
Abbreviations: 
Bx, biopsies; AR, acute rejection; prob AR, probable acute rejection; ATN, acute tubular necrosis; CR, chronic rejection; 
no R, no rejection 
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Borderline changes (n=38) 
Fourteen cases had a clinical diagnosis of AR or probable AR, with a favorable response 
to antirejection therapy in 11 cases and stabilization of moderately impaired graft function 
in three. Thus, the advice in the Banff classification that borderline changes are insufficient 
to justify antirejection treatment must be regarded with caution. 
AR Grades I through III (n*l48) 
The Banff diagnosis correctly identified the eventual clinical diagnosis in 114 (77%). 
A combination of Banff diagnosis AR and a clinical diagnosis CR or no R was seen in 25 
cases (17%). This group consisted of 12 of the 30 cases with grade I AR (40%) and 13 of 
the 118 cases with grades II and III AR (11%). This difference was significant (P < 0.0005; 
Fisher exact test). Therefore, the Banff classification has a tendency to overdiagnosis of AR, 
especially in grade I. In nine cases (6%) with a Banff diagnosis of AR, the clinical diagno-
sis was uncertain (equivocal). In seven of these, antirejection therapy was given with a favo-
rable response in four cases, stabilization of renal function in two, and a rise of serum crea-
tinine in one case. Of the two patients who did not receive antirejection therapy, one patient 
showed spontaneous recovery of graft function, whereas the other lost the graft after sur-
gery for renal artery stenosis. 
Other histological changes (n=24) 
A Banff diagnosis of CR/CsA/ATN/ or other was clinically correct in 22 of these cases 
(92%). Of the two remaining cases, one patient had a suspected posttransplant lymphoma 
in his graft biopsy leading to excision of the graft (clinical diagnosis of AR at biopsy). The 
other patient had a histological diagnosis of combined AR and CsA toxicity. He died of 
myocardial infarction 1 day after installment of antirejection treatment with a lowering of 
the CsA dose (clinical diagnosis probable AR). 
The data in this series suggest that the Banff schema can serve as an acceptable guide-
line for a standardized histological evaluation of renal graft biopsies. A major problem in 
the histological diagnosis is the relative weighting of the respective criteria of AR, such as 
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interstitial infiltrate and tubulitis. For validation of the semiquantitative grading of these 
symptoms, as suggested by Solez et al. , it will be necessary to study the relative importance 
of the different qualitative and quantitative changes in large series. In addition, the diagnos­
tic problems in cases with a complex of changes suggesting AR and CsA toxicity and/or CR 
remain unsolved. 
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INTRODUCTION 
In clinical transplantation the histological diagnosis of acute or chronic rejection can 
be very difficult, since classical hallmarks of these diagnoses, such as interstitial infiltration 
and fibrosis, are far from specific . In renal transplantation the use of Cyclosporine (CsA) 
as immunosuppressive therapy has further complicated the histological evaluation because 
signs of CsA nephrotoxicity show overlap with those of rejection . Since an accurate 
diagnosis of rejection is essential not only to maintain graft function by adequate treatment, 
but also for comparison of results of clinical treatment modalities, attempts have been made 
to standardize the histological criteria used by different centres. For this purpose, analogous 
to similar efforts in cardiac and lung transplant pathology, a large group of pathologists, 
nephrologists and transplant surgeons met in Banff, Canada, and in 1993 Solez et al. pro-
posed a working classification of kidney transplant pathology, the Banff Classification 
(Table 1). In this schema the criteria for rejection are defined, with gradation of pathologi-
cal changes in grades I-III for acute rejection and chronic transplant pathology. For the sco-
ring of histological changes in glomeruli, tubuli, interstitium, and vessels, a numerical 
coding system has been added, together with standards for specimen adequacy and required 
staining techniques. 
Fot acute rejection (AR) the Banff schema emphasizes tubulitis and intimai arteritis as 
the principal criteria (Table 1). The crucial differentiation of innocent or borderline infil-
trates from grade I AR is mainly based on counts of lymphoid cells per tubular cross sec-
tion, and estimation of the extent of the interstitial infiltrate. The authors suggest, as a pos-
sible clinical approach, that no treatment is necessary for borderline changes, while 
histological grade I AR should be treated if clinical signs of graft dysfunction are present. 
For AR grades II and III the indication for antirejection treatment is evident. The patholo-
gy of chtonic rejection (CR) is included in a broader category of "chronic allograft nephro-
pathy", that, because of insufficient criteria for differentiation, may also include changes 
caused by chronic CsA therapy, hypertensive vascular disease, chronic infection, and reflux 
nephropathy . The criteria for diagnosis and grading in this category are discussed in more 
detail in a subsequent publication . 
The introduction of the Banff classification is an important event in the histological 
evaluation of renal graft biopsies. The presentation of internationally accepted definitions 
of histological terms and the delineation of histological criteria have already resulted in 
greater uniformity in the diagnosis of acute rejection in renal allograft pathology. The em-
phasis on tubulitis and intimai arteritis as specific signs for AR is of considerable practical 
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Table 1 
Banff Classification" of renal transplant pathology, diagnostic criteria. 
1. Normal histology 
2. Hyperacute rejection Vascular damage with polymorph accumula­
tion and thrombosis (within 72 nrs after 
transplantation) 
3. Borderline changes No intimai arteritis 
Mild/moderate tocal mononuclear infiltration 
foci of mikt tubulitis (<4 mononuclear cells") 
4. Acute rejection Grade I Significant interstitial infiltration (>25% of 
parenchyma) and foci of moderate tubulitis 
(>4 cells") 
Grade II A) Significant interstitial infiltration and foci of 
severe tubulitis (>10 cells0) and /or 
B) Mild or moderate intimai arteritis 
Grade III Severe intimai arteritis and/or focal infarction 
or interstitial hemorrhage 
5. Chronic allograft 
6. Other changes 
Grade I,II,III Mild, moderate, severe with new onset intimai 
fibrosis as suggestive for chronic rejection0 
a Abridged, Ref #5, 
b Mononuclear cells counted for tubular cross section or per group of 10 tubular cells. 
с More detailed criteria given in Ref #6. 
importance, since these qualitative changes are easily recognized, and provide more objec­
tive criteria than semiquantitative estimation of the interstitial infiltrate. However, before 
the ultimate goal of standardized diagnostic and therapeutic procedures will be attained, 
several problems need further attention. 
First, in the categories borderline changes/grade I AR the discrimination between cases 
that need antirejection therapy from those that do not is not really facilitated. The criteria 
given, with proposed demarcation lines of interstitial infiltration > 25% of the parenchyma 
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and tubulins of > 4 mononuclear cells per tubular cross section, are not sufficient to dis-
tinguish mild rejection from innocent infiltrates. In a recent study, in which we retrospec-
tively compared blindly scored Banff diagnoses in 210 graft biopsies with the eventual cli-
nical diagnoses and the response to therapy, we found clinical rejection in 14 of 38 cases 
(37%) with a Banff diagnosis of borderline changes. By contrast, in 14 of 30 cases (47%) 
with a Banff diagnosis AR grade I, clinical rejection was not present. Similarly, Rush et al. 
found histological rejection according to the Banff criteria in 30% of biopsies in patients 
with stable graft function . The suggestion of the Banff group that grade I AR changes 
should be treated only if clinical signs of graft dysfunction are present, reflects also the over-
lap with borderline changes. Thus, the clinical guidelines for the categories borderline chan-
ges/grade I AR are applicable only in centres that take protocolled sequential biopsies, irre-
spective of graft function. In centres that perform core biopsies only in patients with 
impaired graft function it will be hardly acceptable to withhold treatment when clinical 
signs suggestive of rejection are present and only borderline changes are seen by the patho-
logist, as it is known that in about 25% of the biopsies the changes are patchy, with a high 
risk of sampling error. 
A second problem in the Banff classification is that the grading of AR leans heavily on 
the presence of representative arterial vessels in the core biopsy. This implies that graft 
biopsies without representative arteries must be considered inadequate, as indeed is pro-
posed by the Banff group. From such a point of view it would follow that, to be admissible 
in a trial, patients whose biopsies show no vessels but nevertheless evident AR based on 
tubulitis, should undergo a second biopsy, while the indication for therapy is already appa-
rent. Absence of representative vessels in renal graft biopsies occurs in about 15 - 25% of 
cases, depending on the number of biopsy cores taken. Taking of multiple biopsies is cer-
tainly not a standard procedure in every center. It would therefore seem an option to mark 
all biopsies without vessels, but otherwise adequate, with an additional notation, thus allo-
wing inclusion of such cases in multicenter trials. 
Future studies of the Banff group will further concentrate on chronic graft nephropathy, 
and will also include fine tuning of the schema for acute rejection by better delineation of 
the criteria using relative weighting, and possibly inclusion of immunohistology. However, 
attempts to define discriminative histological criteria for borderline changes and mild AR 
may prove to be futile, because the early histological features in conventional sections are 
essentially non-specific. In the absence of at least moderate tubulitis and/or intimai arteri-
tis the interpretation of a mild interstitial infiltrate remains difficult, since interstitial infil-
trates suggestive for rejection can be found in clinically stable grafts ' . Mild tubulitis is also 
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not entirely specific for AR, since it can occur in stable grafts and also in non-grafted kid-
neys ' . Studies on the relative value of the scores, multivariate analysis of the separate cri-
teria, and reproducibility of the Banff diagnoses are underway. Perhaps an adapted defini-
tion of AR-related tubulitis, including destruction of the basement membrane, and 
excluding lymphoid infiltration in atrophic tubuli, with adjustment of the scoring system, 
may lead to an improved delineation of grade I AR. In the borderline category, with the risk 
of underdiagnosis of rejection inherently related to the patchy distribution of early infiltra-
tion, the advise of the Banff group that no treatment is necessary, clearly cannot depend on 
conventional histology alone. 
With regard to immunohistology, the immunophenotyping of the interstitial lympho-
cytes, or the demonstration of increased HLA-DR expression of tubular epithelial cells have 
not fulfilled their original promise as a reliable diagnostic tool in individual cases . At pre-
sent, attention is given to proliferation markers, and increased expression of cytokines or 
adhesion molecules in rejecting grafts . Also, the increase of macrophages can be used as a 
criterion for AR. Using a CD14 monoclonal antibody (WT14), we demonstrated that in 
AR macrophages are found in a characteristic peritubular distribution , and that the extent 
of this peritubular CD 14 staining showed a practically useful correlation with the probabi-
lity of AR . A widespread peritubular CD14 positivity can sometimes be seen in biopsies 
with only a minimal lymphocytic infiltrate in conventional histology . Therefore we now 
perform routine WT14 stainings in all graft biopsies, and have these available within 24 h, 
simultaneously with the conventional sections. 
In conclusion, the Banff classification is a major step forward in the evaluation of graft 
pathology and is already of substantial importance for international uniformity in histolo-
gical diagnosis and grading of acute rejection. The Banff criteria will certainly allow a more 
reliable comparison of treatment modalities in multicenter trials. The practical clinical con-
sequences are still restricted, since the differentiation between grade I AR and borderline 
changes is still problematic, while AR grade II and III will seldom go undiagnosed in which-
ever system is used. Especially for the crucial discrimination between innocent infiltrates 
and mild rejection further adjustment of the given criteria and/or accessory techniques are 
necessary. 
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INTRODUCTION 
After renal transplantation, an acute interstitial rejection (AIR) is often difficult to dif­
ferentiate from other causes of deteriorating kidney function. In AIR, conventional core 
biopsy and fine needle aspiration biopsy (FNAB) demonstrate an increased number of Τ 
lymphocytes, together with an increase in HLA-DR expression on tubular epithelial cells 
(TEC) . Also, cytological examination of the urinary sediment is used to monitor renal 
transplantation recipients ' . We have studied whether the sensitivity and specificity of this 
approach can be improved by the use of immunocytological staining techniques. To that 
end we have investigated whether increased HLA-DR expression on TEC and Τ lympho­
cytosis can also be demonstrated in urinary sediments and can serve as markers for rejec­
tion. 
Experimental data suggest that treatment with Cyclosporine (CsA) causes a decrease 
in M H C class II expression, implying that an increase of HLA-DR expression on TEC after 
conversion to Azathioprine (Aza) treatment would not be diagnostic for rejection. 
Therefore, we also studied whether conversion from CsA to Aza affects the value of in­
creased HLA-DR expression on TEC as a parameter in the diagnosis of rejection. 
METHODS 
Cytospin preparations from fresh urinary sediments were stained with Papanicolaou, 
MGG, and PAS. For immunocytology they were incubated with monoclonal antibodies 
against the Τ cell markers T i l (Coulter, dilution 1:20), UCHL1, (Dakopatts, dilution 
1:40), and against HLA-DR, (Becton Dickinson, dilution 1:100). After a second incuba­
tion with alkaline phosphatase-conjugated rabbit anti-mouse Ig (Dakopatts, dilution 1:10), 
color was developed with Fast Red and haematoxylin. Preparations were examined by two 
observers who had no knowledge of clinical data. The number of Τ lymphocytes and the 
extent of HLA-DR-positivity of TEC were scored semiquantatively with scores ranging 
from 0 to ++. Rejection was diagnosed when an evident Τ lymphocytosis was present 
together with an increased HLA-DR-expression on TEC. Probable rejection was diagnosed 
when only one of these parameters was present. Absence of both Τ lymphocytosis and 
HLA-DR-expression was interpreted as no signs of rejection. 
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RESULTS 
From 87 urinary sediments of renal allograft recipients, 22 specimens were excluded 
because of predominance of granulocytes due to the existence of urinary tract infection or 
because of absence of TEC (25.3%). Of 23 sediments (20 patients) with an immunocyto-
logical diagnosis of rejection, 19 correlated with clinically and/or histologically proven 
rejection. Four patients had no clinical signs of rejection at the time of positive cytology or 
afterwards (false-positive results). One of these had completed an antirejection treatment 3 
weeks earlier. In 42 urinary sediments (18 patients) no signs of rejection were found. In four 
of these, the results were false-negative. On revision, two of these cases showed moderate 
signs of urinary tract infection. In a third patient the clinical course was that of a chronic 
vascular rejection, although the renal biopsy showed signs of both acute interstitial and 
chronic vascular rejection. In this study the sensitivity of the urinary immunocytology was 
83%; the specificity, 90%. 
For the study of the effects of conversion on the HLA-DR expression of TEC, urina­
ry sediments of 14 patients were examined weekly from 2 weeks before to 4 weeks after con­
version from CsA to Aza treatment. In the majority of cases no increase of HLA-DR expres­
sion on TEC was found. Only three patients showed a definite increase of HLA-DR 
expression together with Τ lymphocytosis. In two of these a rejection developed. In the 
third patient, increased HLA-DR expression on TEC was not followed by clinical signs of 
rejection. 
CONCLUSIONS 
From our data we conclude: 1) Cytological examination of urinary sediments, com­
plemented by immunocytology, is a reliable, simple and noninvasive diagnosticai procedu­
re for monitoring rejection in renal transplant recipients; its sensitivity and specificity are 
comparable to those of FNAB; 2) in the case of AIR the urinary sediment shows Τ lympho­
cytosis and an increased HLA-DR expression on TEC; 3) conversion from CsA to Aza the­
rapy does not affect the reliability of increased HLA-DR expression on TEC as a sign of 
rejection. 
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ABSTRACT 
We have previously reported that during acute rejection of renal allografts Τ lympho­
cytosis and increased HLA-DR expression on tubular epithelial cells can be demonstrated 
in urinary sediments by incubating cytospin preparations with monoclonal antibodies 
against Τ cells and HLA-DR antigen in an indirect alkaline phosphatase technique, We 
now tested whether immunocytological analysis of urinary sediments can be used to diffe­
rentiate acute rejection from other causes of declining graft function. For this we retro­
spectively selected, from a series of urinary samples that were taken either at random or as 
part of a longitudinal study in unselected graft recipients, those specimens that were taken 
at the time of increasing creatinine levels, and compared the original immunocytological 
diagnosis, made without knowledge of clinical data, with the final clinical one. In 44 of 74 
évaluable cases an immunocytological diagnosis of rejection was made, which in 37 patients 
was consistent with the eventual clinical diagnosis. In 28 of 30 cases the diagnosis no rejec-
tion proved to be correct. This indicates a sensitivity of 95% and a specificity of 80% for 
the immunocytological diagnosis of rejection. Of 38 patients who underwent a renal core 
biopsy, the immunocytological diagnosis was consistent with the histological diagnosis in 
36 cases (31 rejections, 5 no rejections). In this subgroup the sensitivity of the immuno-
cytology was 97% and the specificity 83%. We conclude that immunocytological exami-
nation of urinary sediments in renal allograft recipients can be a valuable new tool in dis-
criminating acute interstitial rejection from other causes of deteriorating graft function. 
INTRODUCTION 
Cytological examination of the urinary sediment, as a means to diagnose rejection of 
renal allografts, has been proposed by several investigators " . Already in 1963 Hume et al. 
reported that changes in the urinary sediment of transplant patients can be diagnostic for 
rejection, and can even have a predictive value before deterioration of graft function or 
other clinical signs of rejection are demonstrable . An obvious and important advantage of 
this noninvasive method is that serial testing is possible, giving quick results, without any 
risk for the patient or for the graft. 
The changes in the urinary sediment that have been considered parameters for rejec-
tion have been an increase in lymphocytes and the presence of degenerated or necrotic 
tubular epithelial cells (TEC) ' ' . However, when we applied these criteria in routinely 
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stained preparations of our specimens, we found, like other authors , that it was often 
very difficult to differentiate lymphoid cells from other mononuclear cells or even from 
TEC in the frequently partly degenerated cells in the urinary sediment. Moreover, the pre-
sence of degenerated TEC cannot be taken as a reliable parameter for rejection. Necrotic 
TEC are also desquamated in large numbers during graft dysfunction from other causes, 
especially acute tubular necrosis ' and Cyclosporine A (CsA) nephrotoxicity . Therefore, 
analogously to the immunocytologic staining performed by Bishop et al. on cell suspen-
sions obtained by fine needle aspiration biopsy (FNAB) , we performed additional immu-
nocytologic staining of urinary sediments to enhance the diagnostic value for the diagnosis 
of rejection. We have already demonstrated that immunocyt'ological evaluation of urinary 
sediments is useful to discriminate patients with stable renal graft function from those with 
rejection . We also found that conversion from CsA therapy to azathioprine (Aza) and 
prednisone does not affect the diagnostic value of the used parameters" . In the current 
study we determined the sensitivity and specificity of immunocytologic examination of uri-
nary sediments in discriminating rejection from other causes of deteriorating graft function. 
PATIENTS AND METHODS 
Patients and specimen sehction 
From January 1987 to December 1988 multiple urine samples of renal allograft recipients 
were taken for immunocytological analysis, either at random or as part of a longitudinal study. 
During that time 98 patients developed signs of deteriorating graft function, defined as an 
increase in serum creatinine of more than 25% of the baseline value. In these patients the 
immunocytological diagnosis of the urine sample taken at the time of, or just before (<8 days), 
the increase of creatinine was compared retrospectively with the final clinical diagnosis. Thirty-
eight patients underwent a renal core biopsy after detection of a rise in serum creatinine level. 
In this subgroup the relation between immunocytological and histological diagnosis was eva-
luated separately. Six of the 98 patients had received grafts from living-related donors, 92 recei-
ved cadaver kidneys. The time interval between transplantation and urine sampling varied from 
7 to 410 days. Standard immunosuppressive treatment consisted of CsA in combination with 
low-dose steroids, followed at 12 weeks after transplantation by conversion to Aza with a tem-
porary increase in steroid dose from 10 to 25 mg prednisone per day. The dose of CsA was 12 
mg/kg in the first 4 weeks, with a gradual decrease to 5 mg/kg during the following 8 weeks . 
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Specimen colkction and preparation 
Freshly voided urine samples were processed within 0.5 to 3 h. Aliquots of 10 ml of 
urine were centrifuged for 10 min at 2000 rpm and washed twice in phosphate buffered 
saline (PBS) pH 7.4. After discarding the supernatant the sediment was generally resus-
pended in 1 ml of PBS. Macroscopically highly cellular specimens were resuspended in a 
larger volume of PBS (2 or 4 ml). Cytospin preparations were made by centrifugation (10 
min at 1000 rpm) of 100 μΐ of the resulting suspensions in a cytocentrifuge (Cytospin 2, 
Shandon, Southern Products, Runcorn, UK) and air-dried for at least 1 h. Two cytospin 
preparations were stained with Papanicolaou and May-Grünwald-Giemsa/Wright stain for 
conventional cytology. The other cytospin preparations were fixed in cold acetone (4°C, 10 
min), air-dried, and incubated with 50 μΐ of the CD2 monoclonal antibody (MoAb) T i l 
(Coulter, dilution 1:20, reacting with Τ cells), or with anti-HLA-DR MoAb (Becton 
Dickinson, clone L243, reacting with a nonpolymorphic determinant of the HLA-DR 
antigen, dilution 1:100). MoAbs against keratin (RCK 102, directed against keratin types 
5 and 8, kindly provided by Dr F.Ramaekers, Nijmegen)" and vimentin (RV 202)" were 
included as positive controls for the technique and to test the preservation of antigenic 
determinants on the (often partly degenerated) cells. The CD45RO MoAb UCHL1 
(Dakopatts, Denmark, dilution 1:40), which is known to stain Τ cells even after unfavora­
ble treatments, such as formalin fixation and paraffin embedding , was included to stain Τ 
cells in samples that might have lost their reactivity with T i l . After washing with PBS 
(3 washes, each of 5 min) the slides were incubated with alkaline phophatase-conjugated 
rabbit anti-mouse immunoglobulin (Dakopatts, Denmark, dilution 1:10) for 30 min at 
room temperature. After three further washes in PBS, color was developed with Fast Red 
(20 mg of Fast Red Tr Salt, 4 mg of naphthol As-Mx phosphate disodium, and 4.8 mg of 
levamisole (all of Sigma) in 20 ml ofTris-MgCl, buffer pH 8.2) for 20 min. After washing 
in running tap water the preparations were counterstained with haematoxylin. 
Assessment of the urinary specimens 
The urinary specimens were examined by two observers (I.D., M.J.B.) without know­
ledge of any clinical data, including absence of information about declining graft function. 
Specimens that contained too many granulocytes, too many erythrocytes, or too many epi­
thelial cells of the lower urinary tract, thus obscuring the examination of lymphocytes and 
93 
TEC, were excluded. Also specimens that contained too few TEC or showed degenerative 
changes that impaired the immunocytological staining were excluded from evaluation. 
TEC were identified according to the criteria described by Schumann' . In the T l 1 and 
UCHL1 staining the number of lymphocytes was estimated in a semiquantitative scoring 
system, and indicated as - (no positive cells), ± (few positive cells, normal number with 
respect to other cells present), + (slight increase) or ++ (evident increase). Similarly the 
extent of HLA-DR expression on TEC was scored as - (negative), ± (few positive cells), + 
(many cells moderately positive) and ++ (most TEC moderately to strongly positive). An 
immunocytological diagnosis of "rejection" was made when an evident Τ lymphocytosis 
(++) was seen together with a definite increase (++) in HLA-DR expression on TEC. If only 
one of these parameters was present in a score of++ and the other in a score of+, a diagno­
sis of "probable rejection" was given. A level of + or less of both parameters indicated "no 
rejection". Since we were primarily interested in discriminating "rejection" from "no rejec­
tion" we divided our immunocytological diagnoses into these two categories, including the 
category of "probable rejection" in the "rejection" category. Alterations in the "no rejection" 
group that were suggestive for more specific lesions such as acute tubular necrosis or CsA 
nephrotoxicity" ' were not evaluated for the present study. 
Interobserver variability 
Variations in the cytological diagnoses of the two observers were graded as major, i.e., 
"rejection" vs "no rejection" or minor, i.e., "rejection" vs "probable rejection". In cases of 
both minor and major interobserver variations a consensus diagnosis was made after revi­
sion by both observers, again without knowledge of clinical data. In these cases the con­
sensus diagnosis was the final immunocytological diagnosis. 
Evaluation 
The moment of deteriorating graft function was defined as a rise in serum creatinine 
of at least 25% above baseline level. Rejection was diagnosed clinically when deteriorating 
graft function was combined with one or more of the following symptoms: decrease in 
urine output, increase in body weight, increase in blood pressure, fever, or tenderness of the 
graft (provided that other causes of renal dysfunction had been excluded by echography, 
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radionuclide scan, or angiography). The eventual, definitive clinical diagnosis was based on 
clinical and/or histological data, and response to antirejection therapy. Cases clinically 
determined "no rejection" included cases of CsA nephrotoxicity, surgical and urological 
complications, cytomegalovirus infection, or recurrence of original renal disease. Clinical 
CsA nephrotoxicity was diagnosed when improvement of renal graft function occurred 
within 72 h after reducing the dose of CsA. Two analyses were made. First we compared the 
immunocytological diagnosis with the definitive clinical diagnosis in all patients. The 
second analysis correlated the immunocytological diagnosis with the histological diagnosis 
in a subgroup of 38 patients who underwent a renal core biopsy. 
RESULTS 
From the 98 urinary samples, taken from patients with deteriorating renal graft func­
tion (one sample per patient) 24 (24%) were excluded because of hypercellularity with gra­
nulocytosis or other signs of infection (n=5), predominance of lower urinary tract epithe­
lium and paucity of TEC (n=7), technical staining problems (n=4), or severe degeneration 
with loss of antigenic determinants (n=8). In general the findings in the routinely stained 
cytologic cytospin preparations were largely similar to those reported by others' ' ' . The 
degree of degeneration of TEC varied, and did not prove to be a useful parameter for rejec­
tion or for other causes of renal dysfunction. Possible signs of CsA nephrotoxicity, i.e., iso­
metric vacuolization of TEC, were not evaluated in this series, and epithelial changes sug­
gestive of cytomegalovirus infection were not found. In many cases of acute rejection, 
lymphocytosis was visible in the conventionally stained specimens, but often lymphoid cells 
could not easily be differentiated from other inflammatory cells or even from TEC due to 
nuclear swelling and partial degeneration. For the same reasons we had problems in relia­
bly differentiating lymphocytes from lymphoblasts. Despite this substantial degeneration 
only few specimens (8%) had to be excluded from examination for reasons of loss of immu­
nocytological staining capacity. Positivity forTl 1 was seen as a bright red membranous stai­
ning of lymphocytes (Figure 1 A). The MoAb UCHL1 not only stained Τ lymphocytes, but 
also stained granulocytes, usually with less intensity. The extent and degree of HLA-DR 
expression on TEC was usually easy to estimate, and could, by its cytoplasmic appearance, 
be differentiated from the membranous HLA-DR staining of lymphoid cells (Figure IB). 
Differentiation from positive staining for HIA-DR in macrophages was often more diffi­
cult. The MoAbs against the cytofilamental antigens keratin and vimentin proved to give, 
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Figure I 
Immunocytology of the urinary sediment in acute rejection. A Τ lymphocytosis shown as a dark 
staining of Τ cells with TI J, in an indirect alkaline phosphatase technique. Epithelial celL· and 
granulocytes are negative; В staining with anti-HLA-DR antibody shows increased positivity of 
tububr epithelial cells. The epithelial cells ofbhdder and lower urinary tract are negative, (ori­
ginal magnifications: χ 125). 
apart from their use as positive controls for the staining technique, valuable extra informa­
tion. Anti-vimentin stained the inflammatory cells and, in a variable degree, the degenera­
ted TEC, but was in most cases especially brightly positive in granulocytes. In our alkaline 
phosphatase technique the anti-keratin MoAb RCK 102, directed against keratin 5 and 8, 
and thus reacting with all epithelial cells' , surprisingly stained the TEC especially, where-
96 
Table 1 
Comparison of the Ìmmunocytological diagnosis with the definitive diagnosis. 
ìmmunocytological diagnosis 
Rejection8 
No rejection 
Total number -
44 
30 
Definitive clinical diagnosis 
Rejection 
37 
2 
No rejection 
7 
28 
a Including a diagnosis of "probable rejection." 
as the urothelial cells and the planocellular cells of the lower urinary tract stained only 
weakly or were negative. 
The relation between the Ìmmunocytological diagnosis and the definitive clinical 
diagnosis is shown in Table 1. In the whole group of 74 évaluable patients an Ìmmuno-
cytological diagnosis of rejection was made in 44 cases, which in 37 cases correlated with 
the eventual clinical diagnosis. In 30 of these 37 patients the diagnosis was confirmed his-
tologically, the other 7 cases were treated with antirejection therapy on clinical grounds 
only. All but two responded well, resulting in restored graft function to prerejection levels. 
In two patients the grafts were lost due to irreversible acute rejection and they subsequent-
ly underwent a nephrectomy. Seven patients with a positive immunocytology, however, did 
not show any clinical signs of rejection at the time of examination, or in the following 
months (follow-up time at least 15 months). The eventual diagnoses in these 7 false-posi-
tive cases were: 1) Cytomegalovirus (CMV) infection, confirmed serologically; 2) Recovery 
of posttransplantation acute tubular necrosis; 3) Postrenal obstruction, requiring surgical 
intervention; 4) Mild CsA nephrotoxicity; 5) Recurrence of focal glomerulosclerosis 
accompanied by chronic vascular rejection (confirmed histologically); 6) Transient and 
mild renal dysfunction of unknown cause; and 7) Acute pyelonephritis with microabsces-
ses. Although a renal core biopsy, performed in this last patient, was diagnosed as probable 
acute interstitial rejection (AIR), the renal function recovered after institution of antibiotic 
therapy and without antirejection treatment. Thus, in this patient the Ìmmunocytological 
diagnosis was in accordance with the histological one, but showed a discrepancy with the 
final clinical diagnosis. In 30 urinary samples no signs of rejection were seen, which in 28 
cases was consistent with the final clinical diagnosis. In 5 patients of this group a renal biop-
sy was performed that histologically showed no signs of AIR. The respective histological 
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Table 2 
Comparison of the immunocytological diagnosis with the histological diagnosis. 
Immunocytological diagnosis 
Rejection3 
No rejection 
Total number -
32 
6 
Histological diagnosis 
Rejection 
31 
1 
No rejection 
1 
5 
a Including a diagnosis of "probable rejection." 
diagnoses were: postoperative acute tubular necrosis, probably enhanced by CsA therapy in 
one patient, mbulointerstitial nephritis due to the use of a nephrotoxic antifungal drug in 
one patient and to postrenal obstruction in another patient, and no pathological changes in 
two others. In another patient of this group with negative immunocytology, a renal biopsy 
showed both signs of chronic vascular rejection and AIR, although she did not respond to 
antirejection therapy and developed the clinical course of a chronic vascular rejection. In 2 
specimens the immunocytology was false-negative: both were of patients with clinical signs 
of rejection, who were treated on clinical grounds only, without histological confirmation 
of the diagnosis. Both responded well, although in one patient the improvement of graft 
function might in part have been the result of recovery of posttransplantation acute tubu-
lar necrosis. The causes of the renal failure episodes in the other 22 patients with a correct-
ly negative immunocytology were CsA nephrotoxicity (n=l 1), postrenal obstruction requi-
ring surgical intervention (n=3), chronic vascular rejection histologically proven in 
subsequent months (n=2), nephrotoxicity by antibiotic drug prescribed for urinary tract 
infection (n=2), CMV infection (n=l), acute tubular necrosis (n=l), recurrence of IgA 
nephropathy (n=l), and a transient renal dysfunction of unknown cause (n=l). Compared 
with the final clinical diagnoses of rejection the sensitivity of the immunocytological 
diagnosis was 95%, the specificity 80%. The predictive value of a positive diagnosis was 
84% and the predictive value of a negative test result 93%. The prevalence of rejection was 
53% in this group of patients with deteriorating graft function. The efficiency of the 
immunocytological test was 88%. 
In the second analysis we compared the immunocytological diagnosis with the histo-
logical one in the 38 patients who underwent a biopsy (Table 2). In this group 31 immu-
nocytological diagnoses of rejection and 5 diagnoses of no rejection were consistent with 
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the histological diagnoses. In two cases the immunocytological diagnosis was not correct. A 
false-positive immunocytological diagnosis was made in a patient with the histological 
characteristics of a recurrence of focal glomerulosclerosis, accompanied by chronic vascular 
rejection. A false-negative immunocytological diagnosis was made in a patient who, al-
though the renal biopsy demonstrated both signs of AIR and chronic vascular rejection, did 
not respond to antirejection therapy and developed the clinical course of a chronic vascu-
lar rejection with a very slow deterioration of kidney function, together with proteinuria. 
Compared with the histological diagnosis of AIR as the gold standard, the immunocytolo-
gical diagnosis of rejection in urinary sediments in this subgroup of 38 patients shows a sen-
sitivity of 97% and a specificity of 83%. The predictive value of a positive test result is 97%, 
that of a negative result is 83%. 
Retrospectively we tested whether there were significant differences in the accuracy of 
the original immunocytological diagnoses "rejection" and "probable rejection". In the whole 
group of correct immunocytological diagnoses of rejection (n=37) 5 1 % of cases were ori-
ginally diagnosed as rejection and 49% as probable rejection. In the false-positive group 
(n=7) these percentages were 43% and 57% respectively. In a chi-square test the difference 
between both groups was not statistically significant. 
Interobserver variability 
Major variability in immunocytological diagnoses of the two observers, i.e., "rejection" 
versus "no rejection", was seen in 7% of the original diagnoses, and was corrected by con-
sensus at revision. Minor variability, i.e., a diagnosis of "probable rejection" versus "rejec-
tion", was also seen in 7%. Since both categories were taken together as consistent with 
rejection, these differences had no effect on the analysis of the results. 
DISCUSSION 
The results confirm our previous finding that the inflammatory and epithelial cells in 
the urine, despite degenerative changes, usually retain their antigenic determinants, and 
that immunocytological examination of urinary sediments of renal transplant recipients can 
be a quick, simple and noninvasive procedure in the diagnosis of rejection . The sensitivi-
ty and specificity of our immunocytological examination are within the range of those 
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reported for FNABs" . The degree of interobserver variability in the immunocytologic sco­
ring is acceptable, being in the range ofthat in more standardized cytologic diagnostic tech­
niques, such as cervical smears . The loss of approximately 25% of the urinary specimens, 
due to cellular degeneration or inadequate cellular composite, is in the same range as the 
loss of nonevaluable specimens in FNABs ' . Surprisingly, the immunocytological staining 
results with T l 1 and anti-HLA-DR were often interpretable even when this could not be 
expected from the morphology in the routine cytologic stains. In pilot studies we have tes­
ted other MoAbs reacting with Τ cell membrane antigens (CD3, CD4, and CD7 clusters), 
but staining results with these antibodies were unsatisfactory. Excellent staining, however, 
comparable with that of T l 1, was seen with the MoAb WT82 directed against CD8" . This 
antibody is therefore included in the longitudinal study that we are carrying out at present. 
The presence of large numbers of granulocytes is not infrequently an impediment for 
optimal diagnosis. Increased numbers of granulocytes not only obscure the visibility of 
lymphocytes and TEC, but also make it difficult to determine whether increased numbers 
of Τ cells are the result of a local inflammatory process that induces the granulocytosis, or 
are caused by lymphocytosis in the kidney due to rejection. Assessment of the granulo-
cyte/lymphocyte ratio does not give relevant information in this respect and a search for 
lymphobiasts is not reliable due to degenerative changes. Therefore, sediments with granu­
locytosis should be excluded or interpreted with caution. 
From the findings in immunohistological studies of urological tissues it could be 
expected that RCK 102 would react with all epithelial cells present in the urine"'. The fin­
ding that in the urinary sediments the epithelial cells of urothelial and squamous origin are 
at most weakly positive is probably related to the alkaline phosphatase staining technique, 
since the same antikeratin MoAb stains all epithelial cells when we use an indirect immu-
noperoxidase technique with diaminobenzidine as chromogen. The preferential staining of 
TEC by RCK 102 in the alkaline phosphatase technique is a lucky coincidence, since it 
gives a good indication of the number of TEC present, which is useful in estimating the 
extent and intensity of the HLA-DR staining of these cells in the semiquantitative scoring. 
We did not examine urine samples collected during a standard period of time, because 
in our semiquantitative estimation of the lymphocytosis we took into account the number 
of positive cells in relation to other cells present, and not the absolute count. The extent of 
the HLA-DR expression was, apart from the intensity, also estimated in relation to the 
number of TEC present. 
It is clear that immunocytological examination of the urine cannot be performed in 
patients with absolute anuria. However, even in cases of poor urine flow the amount of 
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urine produced will usually be sufficient for irnmunocytological examination. 
Our results demonstrate that Τ lymphocytosis and increased HLA-DR expression on 
TEC in the urinary sediment show a good correlation with rejection. The sensitivity and 
specificity of the irnmunocytological diagnosis are high, being approximately in the same 
range in the whole group and in the subgroup that underwent a graft biopsy. The fact that 
75% of the cases having a positive irnmunocytological diagnosis underwent a biopsy and only 
17% of the cases with a negative test may have caused a certain bias. This can only be pre­
vented by performing graft biopsies at regular intervals, which is not a policy in our center. 
When we compared the irnmunocytological diagnoses "rejection" and "probable rejec­
tion" with the definitive clinical diagnosis of rejection, we expected a difference in accura­
cy between the two groups. The fact that no significant differences could be found suggests 
that irnmunocytological differentiation between "rejection"and "probable rejection" has no 
practical value, although the low interobserver variation of 7% within these categories 
shows that immunocytologically the differences can be reproducibly recognized. The inter-
observer variation between the major categories "rejection" (including "probable rejection") 
and "no rejection", being also 7%, is comparable to interobserver variation in cervical cyto-
logical diagnosis . Review resulted in consensus and correction. Examination of more than 
one specimen per patient will certainly lead to reduction of incorrect diagnoses, and would 
be advisable in cases in which therapeutic measures,will be taken, based on clinical picture 
and immunocytology of urine alone, and without performing a renal core biopsy. In this 
respect it should also be kept in mind that the histological diagnosis, although in general con­
sidered a "gold standard" for the diagnosis of rejection, is not always easy to interpret, and 
that major discrepancies between diagnoses of different pathologists are far from unusual. 
The value of Τ lymphocytosis and increased I iLA-DR expression on TEC as markers 
for rejection has been demonstrated by several authors . It is obvious that, apart from 
flaws in technique and interpretation, the use of these two markers, may by itself lead to a 
false-positive diagnosis in cases in which these parameters are increased by other causes. 
These are the same factors that hamper the diagnosis in FNABs and even in histology. Thus, 
CMV infection, with lymphocytosis in the graft and increase in HLA-DR expression on 
TEC can easily mimic rejection in the urinary sediment, as it does in FNABs . It is also 
known that rejection is not always accompanied by increased HLA-DR expression, which 
may cause a false-negative result, and, even more important, that increased HLA-DR 
expression can occur in diseases other than rejection ' . It has also been reported that an 
increase in HLA-DR expression during rejection may linger for several weeks after success­
ful antirejection therapy . This may cause a false-positive diagnosis in patients shortly after 
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antirejection treatment as we have observed before . Furthermore, both lymphocytosis and 
increased HLA-DR expression on TEC may occur in stable grafts, especially in the first 
weeks after transplantation, as has been demonstrated in sequential serial renal graft biop-
sies by Fuggle et al.3 and in early biopsies by Raftery et al.35 The fact that in our study the 
presence of both markers showed a good correlation with the occurrence of rejection, may 
be partly related with the time interval between transplantation and immunocytological 
examination of the urine, which in our series ranged from 7 to 410 days. In 4 of the 7 false-
positive cases the urine was examined within 6 weeks after transplantation. 
Although CsA treatment may reduce the level of HLA-DR expression on TEC, as was 
experimentally shown by Milton et al. , our former study showed that conversion from 
CsA treatment to Aza and prednisone, does not adversely affect the reliablity of the immu-
nocytologic diagnosis . 
It seems reasonable to assume that the lymphocytosis in the urine is a consequence of 
lymphocytic infiltration in the tubuli as is characteristically seen in AIR Indeed, the single 
false-negative case in the group that underwent a core biopsy showed histologically an inter-
stitial infiltrate with only minimal invasion of the tubuli. Thus, we expected that intersti-
tial infiltrates due to other causes, such as CMV infection, tubulointerstitial nephritis, 
obstruction, and even the interstitial infiltrates in stable grafts or in CsA nephrotoxicity, 
would less easily lead to lymphocytosis in the urine than in FNABs. However, this hypo-
thesis is not supported by our finding of a false-positive immunocytology in CMV infec-
tion, in obstructive inflammation, and in CsA nephrotoxicity. Incidental findings in a cur-
rent study suggest that lymphocytosis in the urine can also occur, and lead to false-positive 
diagnoses in severe systemic infection accompanied by fever. In these cases the lymphocy-
tosis subsided after successful treatment of the infection. This observation is in accordance 
with the findings of Fidler et al. 
In a previous study, with a longitudinal design , we found preliminary evidence that 
the immunocytological diagnosis of rejection can precede clinical signs of rejection. Similar 
observations have been reported in studies on conventional cytology ' . This finding makes 
it attractive to monitor renal graft recipients on a regular basis, not only in the first three 
months after transplantation, when rejection is more frequent, but also at later stages, when 
the patients regularly visit the outpatient clinic. It can be expected that in several cases a 
diagnosis of rejection can be made at an earlier stage. Whether this will have implications 
for intensifying the immunosuppressive regimen at the time of positive immunocytology, 
in order to control a developing rejection, has to be answered by further longitudinal 
studies. 
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In conclusion, our results show that immunocytological examination of urinary sedi­
ments can be a valuable method for discriminating acute rejection from other causes of graft 
dysfunction. Its sensitivity of 9 5 % and its negative predictive value of 9 3 % show that a 
negative result is a strong argument against the presence of an acute rejection. On the other 
hand, in cases in which clinical criteria for rejection are supplemented by a positive immu-
nocytologic diagnosis, the result of the renal biopsy does not appear to add much to the 
diagnostic accuracy. Our results suggest that under these circumstances antirejection thera­
py might safely be started without the need to confirm the clinical diagnosis by a renal biop­
sy. 
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ABSTRACT 
Immunocytologic examination of urinary sediments (UIC) can be used to discrimi­
nate acute rejection (AR) from other causes of renal allograft dysfunction. In a previous 
study we found that AR was characterized by an increase of Τ cells together with increased 
HLA-DR positivity on renal tubular epithelial cells, demonstrable by immunocytological 
staining on cytospins of sediments in an indirect alkaline phosphatase technique, using 
monoclonal antibodies against CD2 and HLA-DR. The presence of only one parameter 
was scored as probable rejection (PR). To determine whether sequential UIC can be used 
in daily practice to monitor AR, we examined urinary sediments in a group of 121 renal 
transplant recipients during the first 6 months after transplantation, at regular intervals. 
Microscopic examination was blinded and retrospectively correlated with clinical and his­
tological data. Overall, the percentage of inadequate urine samples was 28%. A clinical AR 
(histologically confirmed in 52 cases) developed in seventy-two of the 121 patients (59%). 
Adequate UIC was available in 57 of 72 rejection episodes, and in 51 cases (90%) the UIC 
diagnosis was correct (38xAR,13xPR). In 3 of the 6 false-negative UIC diagnoses the con­
comitant renal core biopsy showed acute vascular rejection without an interstitial compo­
nent. In 23/51 cases with clinical and cytological AR the UIC diagnosis (AR or PR) prece­
ded the clinical signs of AR by 2-35 days (mean 11±2). In 49 stable patients UIC was 
positive in 345 of 1098 (31%) samples (l43xAR, 202xPR). We conclude that the low inci­
dence of false-negative diagnoses makes UIC a sensitive method to rule out AR. The high 
incidence of false-positive diagnoses is in accordance with previously reported findings in 
sequential core biopsies. It limits the diagnostic value of UIC, especially in the absence of 
clinical signs of rejection. 
INTRODUCTION 
Severe acute rejection (AR) of a renal allograft may develop within 24 hours without 
premonitory clinical signs. To prevent such alarming situations with their accompanying 
risks of graft loss, several methods have been proposed to monitor the graft or to identify 
patients at risk for rejection. Apart from sequential routine examinations of blood pressure, 
general condition, determination of graft function by creatinine level and determination of 
cytokines in the circulation, more direct information of the events in the graft can be gained 
from sequential protocol core biopsies" , fine needle aspiration biopsies (FNAB)" , or 
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examination of the urinary sediment' " . Although the risks of FNAB are lower than those 
of repeated core biopsies" , both techniques are invasive, and not without inconveniences 
for patients and physicians . In previous studies we found that the immunocytological 
demonstration of an increase of Τ cells and an increased HLA-DR expression on exfoliated 
tubular epithelial cells (TEC) in the urinary sediment can be used as a marker for AR . In 
patients with declining graft function urinary immunocytology (UIC) can help to discri­
minate AR from other causes of graft failure, such as Cyclosporine (CsA) toxicity or surgi­
cal complications . In the current study we tested in a large group of patients whether 
sequential UIC can be used to monitor AR in daily practice, and, preferably, even predict 
AR after renal transplantation. This would enable clinicians to detect rejection at an earlier 
stage, and install adequate therapy without the necessity of taking a core biopsy. 
MATERIALS AND METHODS 
Patiente 
All 129 adult patients who received a renal allograft from a cadaveric (n= 117) or living 
related (n=12) donor between November 1988 and June 1990 entered the study. Urinary 
sediments were taken twice weekly during the clinical period which lasted about 3 weeks in 
uncomplicated cases. Thereafter samples were collected during each visit at the outpatient 
clinic, i.e. at protocol controls twice weekly during the first month, once weekly during the 
second and third month, and once in two to four weeks during the next three months after 
transplantation. Patients with signs of deteriorating graft function underwent diagnostic 
procedures, including a core biopsy, irrespective of the findings in the urinary sediment. 
Children (recipients under the age of 18 years) were excluded from analysis. Standard 
immunosuppressive treatment consisted of CsA, in a dose of 12 mg/kg/day during the first 
month, with a gradual reduction to 4 mg/kg/day in the following two months, in combi­
nation with low-dose steroids (10 mg daily). At 12 weeks after transplantation patients were 
randomly selected for either conversion to azathioprine (Aza) with a temporary increase in 
steroid dose from 10 to 25 mg prednisone per day, or continuation of CsA with a gradual­
ly reduction of the prednisone dose to zero, as the two arms of a randomized study . From 
July 1989 on, the immunosuppressive regimen was intensified by a slower tapering down of 
the prednisone dose and by substituting the oral CsA solution by capsules. Acute rejection epi­
sodes were treated with methylprednisolone (1 g i.v. on 3 consecutive days), or antithymocyte 
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globulin (RIVM Bikhoven, The Netherlands; 200 mg i.v. on alternate days for 10 days). 
Preparation and staining of urine sediments 
Freshly voided morning urine was processed as described earlier'1. Briefly, aliquote of 
10 ml of urine were centrifuged (10 min at 2000 rpm), and the sediment was, after two 
washings in phosphate buffered saline (PBS) pH 7.4, resuspended in 1 ml of PBS. Cytospin 
preparations were made by centrifugation (10 min at 1000 rpm) of 100 μΐ of this suspen­
sion in a cytocentrifuge (Cytospin 2, Shandon, Southern Products, Runcorn, UK), air-
dried, and for conventional cytology stained with Papanicolaou and May-Grünwald-
Giemsa/Wright stain. For immunocytological staining a standard indirect alkaline phos-
phatase technique was used, as described before . The monoclonal antibodies (MoAbs) 
used for the first incubation were T i l (anti-CD2, Coulter, dilution 1:20)"', WT82 (anti-
CD8, Dr. W. Tax, Nijmegen)28, UCHL1 (anti-CD45RO, Dakopatts, dilution 1:40)26, and 
anti-HLA-DR (Becton Dickinson, clone L253, dilution 1:100)"'. In addition MoAbs 
RCK102 (anti-keratin types 5 and 8" and RV202 (anti-vimentin , Dr F. Ramaekers, 
Maastricht) were used as positive controls for the technique and for assessment of the pre-
servation of antigenic determinants on the sometimes partly degenerated cells. 
Immunocytological diagnosis 
The cytological and immunocytological slides were examined by one of us (ID) with-
out knowledge of clinical data or of the histology in case of a simultaneously performed core 
biopsy. Specimens that posed diagnostic difficulties (6%) were examined by a second obser-
ver (MJB), and a consensus diagnosis was made. Samples containing granulocytes, ery-
throcytes, and/or epithelial cells of the lower urinary tract in numbers that impaired adequate 
identification of lymphocytes and TEC were considered inadequate. Similarly, hypocellu-
lar specimens with insufficient TEC, or with severe signs of degeneration impairing immu-
nocytological staining were excluded. TEC were identified according to the criteria described 
by Schumann and by positive staining with the anti-keratin MoAb. The specimens were 
assessed in a semiquantitative way, as described before" , and scored as - (no positive cells), 
± (positive cells present), + (slight increase in positive cells) and ++ (evident increase of posi-
tive cells). For quantitation of the HLA-DR expression both the number and the intensity 
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of the staining of the TEC were taken into account. The number of positive cells was 
estimated in relation to other cells present, as we did not attempt to obtain quantitative data 
on cells shedded within a fixed period or in a fixed volume of urine. An UIC diagnosis of 
AR was based on evident Τ lymphocytosis (++) together with a definite increase (++) in 
HIA-DR expression on TEC. Τ lymphocytosis was in general diagnosed when all three 
Τ cell stainings ( T i l , WT82, and UCHL1) were positive, but in suboptimal slides one or 
two positive Τ cell stains could be sufficiently convincing to result in a ++ score. A diagno­
sis of probable rejection (PR) was made when one of the two parameters was scored as ++ 
and the other as + or less. A score of + in one parameter and + or less in the other was scored 
as negative for AR. 
Evaluation 
Retrospectively the blindly scored UIC diagnoses were related to the clinical and histo­
logical data over the 6 months of the study period. Clinical rejection was defined as a com­
bination of a raised creatinine level with one or more of the following symptoms: decrease in 
urine output, increase in body weight, increase in blood pressure, or fever, local pain and/or 
swelling of the graft, while causes of graft dysfunction other than rejection had been exclu­
ded by echography, radionuclide scan, or angiography. The clinical diagnosis was, in the 
absence of contraindications, verified by taking a core biopsy of the graft. The primary his­
tological diagnoses for clinical purposes were made according to standard criteria " ', with 
knowledge of clinical data. For the retrospective evaluation we used retrospectively and 
blindly scored (MJB) diagnoses according to the criteria of the Banff Classification , 
with scoring of the diagnostic categories: 1) Normal histology; 2) Hyperacute rejection; 
3) Borderline changes; 4) Acute rejection grade I-III; 5) Chronic allograft nephropathy 
grade I-III; and 6) Other changes not considered to be due to rejection. For the eventual 
analysis of each episode of renal dysfunction the UIC diagnoses were compared with the 
definitive clinical diagnoses, retrospectively made, and based on combined evaluation of cli­
nical data, histological diagnosis and response to antirejection therapy or other treatment. 
These final clinical diagnoses were categorized as: 1) AR with favorable response to antire­
jection therapy; 2) Probable rejection (PR) with incomplete or no response to therapy; 
3) Chronic rejection with proteinuria and gradual loss of renal function; 4) Uncertain 
diagnosis; and 5) No rejection. The latter category included CsA nephrotoxicity, postrenal 
obstruction, vascular occlusion, and acute tubular necrosis. 
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Statistical analysis 
Proportions were compared with Chi-square analysis. A p-value smaller than 0.05 was 
considered statistically significant. Mean values are given ±SEM. 
RESULTS 
Patients 
In eight of the 129 renal transplant recipients who entered the study UIC was not pos-
sible because of anuria, due to primary nonfunction or rapid graft failure, caused by throm-
bosis of graft vessels (n=4), massive untreatable bleeding requiring transplantectomy, recur-
rence of hemolytic uremic syndrome, irreversible acute rejection, and admission to another 
hospital for pancreatitis soon after transplantation. Of the remaining 121 patients, 101 
could be followed for the entire study period of 6 months. Of the other 20 patients, nine 
died during the study period ( 10.6± 1.6 weeks after transplantation), as a result of infectious 
complications (n=6), cardiovascular complications (n=2), and hepatic failure after anesthe-
sia (n=l). Eleven patients suffered irreversible graft loss due to rejection (n=10) or unsuc-
cessful repair of renal artery stenosis (n=l), and returned to dialysis. 
Adequacy of the urinary specimens 
In the total group of 121 patients 2832 urine sediments were available for study. Of 
these 2047 (72%) were adequate for analysis. The causes of inadequacy are summarized in 
Table 1. As shown, inadequate specimens were more frequent in the first week after trans-
plantation, mainly due to a high incidence of contamination with blood. After this week 
the frequency of inadequate specimens remained more or less stable at 26% over the whole 
period. Hypocellularity was relatively scarce and mostly found in specimens from stable 
grafts (41/63) or shortly after antirejection therapy (11/63). CsA-treated patients showed a 
higher incidence of inadequate samples than Aza/prednisone-treated patients (485/1624 vs 
186/773, 30% and 24% respectively, p=0.003) but this difference could be related to the. 
high number of inadequate specimens in the first week. When we compared the specimens 
in patients of both groups during a period of antirejection therapy we found inadequate 
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Table 1 
Causes of inadequacy of urinary sediment preparations in samples taken in the first week after 
transplantation and during the later period. 
Week 1 after 
transplantation 
Week 2-26 after 
transplantation 
No. of inadequate samples/ 
total no. of samples taken 100/182 (55%) 685/2650 (26%) 
Causes of inadequacy 
hematuria 
granulocytosis 
and/or infection 
inadequate technique 
hypocellularity/ paucity of TEC 
severe degeneration 
74 
15 
5 
3 
3 
(74%) 
(15%) 
(5%) 
(3%) 
(3%) 
110 
392 
80 
60 
43 
(16%) 
(57%) 
(12%) 
(9%) 
(6%) 
samples in 37/126 (29%) specimens in the CsA group and 53/219 (24%) in the Aza-treated 
group (NS). 
Urinary immunocytology in clinically stable patients 
In forty-nine patients (41%) clinical AR did not develop during the period of study. 
Of the 1098 adequate urinary sediments examined in this group, 143 (13%) were diagno-
sed as AR (both markers ++) and 202 (18%) as PR (one marker ++). As illustrated in 
Figure 1, in this clinically stable group positive sediments were seen during the whole period 
of study. In only 6/49 stable patients all sediments were consistendy negative for rejection. 
Six patients had only one positive sediment during the period of study, three scored as AR 
and three as PR. In the remaining 37 patients the number of positive UIC diagnoses varied 
from 2 to 23 specimens (7±0.9) per patient with comparable frequencies for the scores AR 
and PR. In 12 patients the UIC was scored as positive during a period of infectious com-
plications, either urinary tract infection (9 patients, 20 specimens) or CMV infection (3 
patients, 17 specimens). Two patients with a positive score demonstrated a temporary 
decline of graft function, with a picture of AR grade I in the concomitant core biopsy, in 
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Figure 1 
UIC results in the group of49 stable renal transphnt recipients for each post-transpL· 
week during the folhw-up period. 
Table 2 
Diagnostic value of UIC at the time of a serum creatinine increase of 25% or more above base 
line level. Comparison with the definitive clinical diagnosis. 
Definitive clinical 
Immunocytological No. with rising diagnosis 
diagnosis serum creatinine 
Rejection No rejection' 
AR + PR" 69 56 13 
Other 46 7 39 
a Cases with graft dysfunction due to other causes, including CsA nephrotoxicity, postrenal obstruction, ATN, 
and infection, 
b Acute rejection and probable rejection. 
one case combined with chronic rejection grade I, and in the other with CsA nephrotoxi-
city. In these cases no antirejection therapy was given, since graft function improved spon-
taneously in one patient and remained stable in the second parient. 
Urinary immunocytology as a diagnosta test at the time of declining graft function 
For evaluation of the diagnostic accuracy of UIC at the time of deteriorating graft 
function we retrospectively compared the definitive clinical diagnoses (based on clinical 
parameters, histology, and response to therapy) and the UIC diagnoses in 99 patients who 
experienced a total of 166 periods of increase of serum creatinine of 25% or more above 
baseline level. In 115 of these 166 periods adequate UIC specimens were available at the 
relevant time. When considering the UIC diagnoses AR and PR both as positive, we found 
a correct UIC diagnosis in 56 of 63 (89%) periods of clinical rejection, while in 39 of 52 
(75%) cases without rejection UIC was scored as negative (Table 2). Clinical AR developed 
in two of the 13 patients with "false-positive" UIC diagnosis, 25 and 53 days later, after 
consistently positive UIC (AR and/or PR), and five patients had completed antirejection 
therapy 5-37 (15±6) days earlier. Another patient showed interstitial infiltration in the core 
biopsy, but was eventually diagnosed as having CsA nephrotoxicity on clinical grounds. Of 
the seven cases with a "false-negative" UIC diagnosis two had vascular rejection without 
interstitial infiltration (Banff AR grade IIB), and a third had chronic rejection with focal 
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Table 3 
Comparison of T11 and HLA-DR as separate markers for acute rejection in 115 episodes of 
deteriorating graft function (increase in serum creatinine of 25% or more above base level). 
Rejection marker(s) 
with score 
T11 HLA-DR 
++ 
+ 0Γ++ 
'. + + '•• 
+ 0Γ++ 
Sensitivity 
(%) 
73 
83 
70 
94 
Statistical properties 
Specificity 
(%) 
79 
65 
71 
29 
Pos predictive 
value(%) 
81 
74 
75 
61 
Neg predictive 
value{%) 
71 
76 
66 
79 
interstitial infiltration. Compared to the final clinical diagnosis of rejection the sensitivity 
of the UIC diagnosis was 89%, the specificity 75%. The predictive value of a positive UIC 
diagnosis was 8 1 % and the predictive value of a negative UIC result 85%. The prevalence 
of rejection in this group with deteriorating graft function was 55%. 
To assess the relative contribution of the individual markers (T lymphocytosis and 
increased HLA-DR expression on TEC) to the UIC diagnosis, we calculated the specifici­
ty and sensitivity for AR in sediments for each marker (Table 3). The data suggest that the 
T l 1 score is more helpful in distinguishing rejection from other causes of renal dysfunction 
than the extent of the HLA-DR positivity of TEC, which is less specific. 
Urinary immunocytohgy before and after rejection episodes 
Seventy-two patients (59%) showed one or more episodes of clinical AR in the first six 
months after transplantation. For evaluation of the UIC diagnoses at the time of AR we 
used the scores of the last sediment made before clinical signs of AR and/or installment of 
antirejection therapy. In 10 cases the urinary specimen was inadequate: due to hematuria 
(n=4), technical staining problems (n=3), urinary tract infection (n=2), or severe degenera­
tion (n=l). In five cases the relevant sediment was not available because of severe oligu­
ria/anuria (n=3) or logistic problems (n=2). In the remaining 57 cases the time span 
between urine collection and diagnosis of AR was, according to the schema of sampling, 
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Table 4 
Immunocytological and histological diagnoses in patients with first episode of clinical rejection: 
Immunocytological 
diagnosis 
Rejection 
Probable Rejection 
No Rejection 
Total 
No.b 
38 
13 
6 
57 
histology 
available 
31 
7 
6 
44 
ВС 
2 
-
1' 
3 
Histological diagnosis in Banff Classification 
AR 
g r i d 
6 
2 
1 
9 
AR 
gr ИА±В 
17 
3 
1 
21 
AR 
gr IIB8 
1 
2 
3 
6 
AR 
gnu 
5 
-
-
5 
a Of 72 patients with first episode of clinical rejection adequate urinary samples were available in 57 cases. 
b Cases with adequate UIC at time of clinical diagnosis. 
с ВС: borderline changes according to the criteria of the Banff Classification. 
d AR gr Ι,ΙΙ,ΠΙ: acute rejection according to the criteria off the Banff Classification. 
Category HB with intimai arteritis, but without widespread interstitial infiltrate as seen in IIA±B. 
f With isometric vacuolization suggestive of CsA nephrotoxicity. 
maximally 4 days in the first month, maximally 6 days in the second and third month, and 
2-3 weeks in the following 3 months. At the time of rejection the UIC diagnosis on the rele­
vant sediment was positive in 51/57 patients (90%), being AR in 38 (67%) and PR in 13 
(23%) cases. In 44/57 cases a concomitant core biopsy was available. Table 4 summarizes 
the histological diagnoses in the different categories of UIC diagnosis. As it is assumed that 
the cells in the urine are the result of interstitial rejection and are less related with the vas­
cular rejection component, we distinguished a histological category AR grade IIB compri­
sing the cases in which the diagnosis of AR was mainly based on intimai arteritis and not 
on the presence of a widespread interstitial infiltrate. As shown in Table 4, in this category 
with predominant vascular rejection 3/6 biopsies had a false-negative UIC diagnosis, to be 
compared to 1/21 biopsies in category AR grade IIA±B, and 1/9 in category AR grade I. 
Figure 2A shows the time relationship between the sequential UIC findings and the 
rejection event in 44 cases in which the diagnosis was confirmed by a concomitant core 
biopsy. Before clinical signs were evident the sediment was consistently scored as AR for a 
period of 11±2 days (range 2-35) in 17 patients and in general a diagnosis of PR had been 
given in the preceding 7 days (18±3.5 days before clinical signs, range 9-42 days). In six 
patients only one ++ marker (score PR) preceded clinical rejection. In the six patients with 
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Figure 2 
Time relationship between UIC and histologically confirmed rejection, from 8 weeks before 
until 8 weeks afier (B) rejection in 44 renal transplant recipients. 
negative UIC at the time of rejection the sediments had been continuously negative and 
remained so after therapy. 
After installment of therapy, there was in general not a quick return to a negative UIC 
diagnosis (Figure 2B). In 13 patients the UIC score remained continuously positive, and a 
second rejection developed in 7 of these, 13-73 days (30±9) after the first, that rapidly resul­
ted in irreversible renal failure in four of these seven. In 16/44 patients with AR the UIC 
became negative, after a period of 3-84 days (29±7). Only one of these 16 patients had a 
second rejection, at the end of the study period. Eight patients showed reappearance of 
positive markers in the UIC after an interval of three or more negative sediments, and a 
second rejection developed in four of these. In a fifth patient the biopsy showed rejection, 
but graft function recovered without antirejection treatment. In one patient rejection 
occurred at the end of the follow-up period. 
DISCUSSION 
Our results confirm that AR in renal allografts is reflected by lymphocytosis and in­
creased HLA-DR expression of TEC in the urine, consistent with our earlier reports ' and 
those of other authors using similar cytological and immunocytological techniques ' ' . 
Most studies on urinary markers for AR have concentrated on Τ lymphocytosis as the hall­
mark for the diagnosis, often in combination with one or more other markers. Apart from 
HLA-DR expression on TEC, the additional markers included CD25 staining of lympho­
cytes" , and ICAM-1 staining of TEC '. Reported sensitivities for the urinary diagnosis of 
AR range from 56% to more than 90% " "" . It is clear that such a high sensitivity with 
the possibility to diagnose AR in a preclinical stage, and the easy availability of the urine, 
would make UIC an attractive standard procedure for monitoring of rejection, if not the 
restricted specificity would be a major drawback that reduces the practical value of a posi­
tive diagnosis. This is illustrated in our group with stable grafts, in which 3 1 % of the sedi­
ments had a positive score in the absence of clinical rejection. In patients with deteriorating 
graft function, in which rejection has to be differentiated from other causes such as CsA 
toxicity, the specificity is higher, and in such a clinical situation absence of Τ lymphocyto­
sis in an adequate UIC argues against AR: in the group with deteriorating graft function the 
predictive value of a negative UIC diagnosis was in the present study 85% (39/46) when 
compared to the definitive clinical diagnosis, and 45% (9/20) when compared to the his­
tology. A handicap, that UIC shares with other diagnostic tests such as FNAB and even core 
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biopsies, is that a predominantly vascular AR, with minimal interstitial infiltrate, may escape 
detection. Although improvements of the sensitivity of the UIC technique can be expected 
from the use of more or other markers , or from the use of flow immunocytometry , it is 
unlikely that the problem of the predominantly vascular rejection, in our study comprising 
13% of all cases of AR, can be solved by cytological techniques alone. 
For monitoring of AR the restricted specificity of positive findings as evident in our 
group with stable graft function, represents the major problem in the use of UIC. UIC shares 
this problem with most other diagnostic techniques, such as serological tests' , monitoring 
of interleukin 2 receptor expression on peripheral blood lymphocytes , monitoring of 
mononuclear cells in the circulation , and even core biopsies . At present most clinicians 
will not consider positive findings in one or even several diagnostic tests a sufficient indi-
cation for antirejection treatment when there is no accompanying clinical evidence of graft 
dysfunction . The lack of specificity of diagnostic tests based on increases of lymphocytes 
and/or HLA-DR expression on TEC can be explained by the finding that interstitial infil-
trates, histologically and immunohistologically identical to those of rejection, can be pre-
sent in biopsies of stable grafts that never show AR . Rush et al. reported that in clinically 
stable patients 3 1 % of protocol renal allograft biopsies, serially taken at 1,2, and 3 months 
posttransplant, showed histological rejection. Likewise, increased HLA-DR expression on 
TEC in stable grafts has been demonstrated in serial biopsies by Fuggle et al. , and in early 
biopsies by Raftery et al. Only part of these infiltrates can be related to infectious dis-
eases . In our series infection could have played a role in six cases of the group with stable 
graft function. Whether interstitial infiltrates without more specific signs of AR such as 
tubulitis and/or arteritis in stable grafts should be considered as innocent infiltrates or as 
signs of subclinical rejection, has been a matter of debate. In general, infiltrates in protocol 
biopsies have not been considered an indication for antirejection treatment, unless clinical 
signs of rejection are apparent . In our series, grafts that after treatment of AR recovered 
with consistently negative UIC showed a better outcome than grafts with consistently posi-
tive UIC (recurrent AR in 1/16 vs 7/13 patients within the study period). This is consistent 
with recent studies of Rush et al. who found that the presence of interstitial infiltrates in 
stable grafts correlated with an unfavorable course . In protocol biopsies (at 1,2,3,6, and 
12 months after transplantation) they found that the severity of the inflammatory reaction, 
as scored according to the Banff schema, corresponded with an increasing risk of develop-
ment of AR. After one year, excellent function and normal histology were only seen in 
patients with the lowest cumulative inflammatory score. In a subsequent prospective 
randomized study, Rush et al. considered infiltrates in stable grafts as signs of subclinical 
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rejection, and consequently treated the patients with interstitial infiltrates with high-dose 
steroids, regardless of graft function or other clinical data. They compared renal function 
and histology in a treatment group, that underwent protocol biopsies, with the results in a 
control group in which only a biopsy at 6 months was performed. It appeared that treat-
ment of subclinical rejection during the first 6 months did not improve renal function at 6 
and 12 months . Since only 52 of the 76 stratified patients completed 12 months thusfar, 
the follow-up may have been too short to demonstrate differences in eventual outcome, 
especially with regard to chronic graft failure. Longterm follow-up is required for definiti-
ve assessment of the effectiveness of treatment of subclinical rejection episodes, in terms of 
graft survival and long term graft function. If such effectiveness could be demonstrated, 
UIC can be a valuable adjunct in the monitoring of graft infiltration, certainly when it, as 
a noninvasive method, could be used as an alternative for protocol biopsies. 
In the present series the overall percentage of inadequate sediments was 28%. When 
we exclude the first week after transplantation, in which inadequacy is more frequent and 
often caused by blood contamination, the number of inadequate sediments was 26%. This 
number is consistent with that in our previous study in which relatively few samples were 
taken within the first week '. In general, materials obtained for cytologic examination show 
a higher incidence of inadequacy than biopsies for histology. In FNABs percentages of 
inadequate specimens are reported as 22.5% ì and 21.6% . Compared with FNAB, a 
higher incidence of inadequate samples can be expected with UIC, first because of oligu-
ria/anuria and secondly because of degeneration of cells caused by the prolonged presence 
in urine at body temperature. This latter problem, which we originally expected to form a 
major obstacle, only accounted for 6% of the inadequacies in our series, leaving granulocy-
tosis, with obscuring of the cytological picture by masses of intact or degenerated granulo-
cytes, as the most important impediment for adequate examination. This granulocytosis 
usually occurred in subsequent samples of the same patients. 
In our opinion improvements of UIC as a diagnostic tool for AR should concentrate 
on automation and standardization with the use of a panel of markers preferably including» 
in addition to Τ cell markers and HLA-DR, activation markers such as CD25" and 
CD54 . Τ lymphocytosis remains the hallmark for the diagnosis of AR, with higher sensi­
tivity and specificity than HLA-DR expression on TEC, as evident from the present and 
another study , while a combination of markers improves the accuracy. Combination of 
conventional cytology and flow immunocytometry may offer further advantages. Using 
such a combination for urinalysis Roberti et al. reported a sensitivity of 100% with a spe­
cificity of 9 3 % for the diagnosis of rejection' . Flow immunocytometry allows a rapid ana-
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lysis and considerably reduces the heavy workload of studying multiple immunocytological 
stainings in large numbers of sediments. It may also offer a possibility to reduce the inci­
dence of inadequate samples caused by granulocytosis, contamination with blood, or tech­
nical failures. 
From the present study we conclude 1. That UIC gives relevant information on the 
presence of an inflammatory Τ cell reaction in the graft, 2. That a negative UIC diagnosis 
has a high predictive value with regard to the absence of acute rejection, 3- That a positive 
UIC diagnosis does not necessarily indicate ongoing rejection but probably indicates that 
an inflammatory reaction is present in the graft. A possible clinical relevance of such a posi­
tive diagnosis in the absence of clinical rejection has to be assessed in future studies in which 
graft survival and long term graft function are compared between groups of patients with 
and without alterations in immunosuppressive regimen solely based on positive UIC 
findings in the first year after transplantation. 
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CHAPTER 10 
SUMMARY 

SUMMARY 
Renal transplantation is now an accepted treatment of patients in end-stage renal fail­
ure. Over 30,000 kidney transplantations have already been performed throughout the 
world. Although patient and graft survival rates have improved during the years, long term 
results are still far from ideal: 30-40% of kidney grafts fail within 5 years mainly due to 
chronic rejection with its insidious damage to the graft. The development of one or more 
acute rejection episodes has proved to be an unfavorable prognostic determinant for long 
term graft survival " . It is, therefore, very important to diagnose an acute rejection as early 
as possible to maintain, or better, restore renal function. However, in many cases the 
diagnosis of rejection is not easily made. During the years many efforts have been made to 
extend and improve the diagnostic repertoire. New immunostaining techniques have been 
developed and applied on renal allograft biopsies since the early 1980s, when several MoAbs 
became available. H1A-DR antibodies have been used for this purpose. Although rejection 
is accompanied by an increased expression of class II M H C antigens (HLA-DR) on TEC, 
this increase is far from specific for rejection , and is also not invariably present during rejec­
tion . In FNABs, rejection can be demonstrated by the presence of Τ lymphocytosis, 
whereas this parameter is less valuable in renal core biopsies. The presence of increased 
numbers of macrophages, however, indicative for acute rejection in FNABs, has been repor­
ted in renal biopsies too . Initially this rejection parameter escaped from detection 
especially because of technical staining problems. Many anti-monocyte/macrophage 
MoAbs gave only weak or variable staining results, or showed insufficient contrast. A new 
anti-monocyte/macrophage MoAb WT14, that recognises the CD14 cluster of differentia­
tion, was developed in our laboratory. In cell suspensions WT14 reacts with human mono­
cytes and macrophages, and shows a membranous distribution. In tissue sections WT14 
reacts with intravascular monocytes, histiocytes, tissue macrophages, dendritic cells, and in 
a less intense and more variable manner with endothelial cells of medium-sized and small 
blood vessels. 
In a retrospectively selected series of renal allograft biopsies we compared the staining 
pattern of WT14 in an indirect immunoperoxidase technique with that of other anti-mono­
cyte/macrophage antibodies, a nonpolymorphic HLA-DR determinant, and the CD2 
MoAb T i l (Results described in chapter 2). All 44 biopsies of patients with a clear-cut 
acute rejection, clinically as well as histologically proven, showed a diffuse interstitial incre­
ase of WT14-positive cells with a characteristic peritubular pattern. This pattern was absent 
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in normal kidneys (n= 10), in the biopsies of patients with CsA nephrotoxicity (n=9), chronic 
vascular rejection (n=13), and various other renal diseases (n=60). In normal kidneys only 
dispersed WT14-positive cells were present, that resembled dendritic cells and that were 
commonly lying in close proximity of the peritubular capillaries. The WT14 staining was 
more specific for rejection than the HLA-DR expression on TEC, which was increased in 
many other lesions. Five of 8 biopsies of patients with CsA nephrotoxicity showed a definite 
HLA-DR increase on TEC, 3 having a pronounced and 2 a moderate degree of HLA-DR 
expression. In chronic vascular rejection, HLA-DR expression on TEC was increased in 11 
of 13 patients, whereas in 39 of 60 nontransplanted patients with various renal diseases an 
increased HLA-DR expression was seen. Comparative staining with other anti-monocyte/ 
macrophage MoAbs showed superior results of the WT14 staining which appeared to be 
more consistent and more intense. 
Like most MoAbs, however, WT14 can only be applied to cryostat sections. The fre-
quently small size of renal core biopsies makes a separate workup of part of the tissue for 
immunohistology often impossible. Therefore the new CD68 anti-monocyte/macrophage 
MoAb KP 1, that can be applied to routinely processed, even Bouin-fixed, tissues seemed 
very promising. In chapter 3 we describe the results of this KP1 staining in 27 retrospec-
tively selected biopsies: 16 rejection biopsies and 11 control biopsies without acute rejec-
tion (4 recurrences of original glomerular diseases, 3 CsA nephrotoxicity, 2 ATN, 1 renal 
artery stenosis, and 1 normal histology). Using an ocular grid we counted the KP1-positive 
mononuclear cells in 10 cortical high power fields that were representative for the whole 
cortical area. In 25 of the 27 biopsies macrophages were strongly KPl-positive. Two rejec-
tion biopsies were completely negative, probably due to prolonged fixation. In the remai-
ning 14 rejection biopsies the number of KPl-positive cells was significantly higher than in 
the controls (1184 ± 410 per mm" (mean ± SD) vs 112 ± 126 per mm ). Especially in cases 
in which frozen tissue is not available the demonstration of increased numbers of monocy-
tes and macrophages with KP1 on routinely fixed biopsies can be a helpful adjunct in the 
diagnosis of acute rejection, provided fixation times are kept within the recommended 
limits of l-3h. However, immunohistological staining of cryostat sections with WT14 
remains the method of choice. 
In search of a quantitative marker by which the extent of the peritubular WT14 posi-
tivity could be considered an indication for acute rejection, we compared the extent of peri-
tubular WT14 staining with: a) The original histological diagnosis, made with knowledge 
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of clinical data; b) The retrospectively and blindly scored histological diagnosis according 
to the Banff criteria; and c) The definitive or final clinical diagnosis, made retrospectively 
with additional data on response to therapy. In a total of 154 unselected renal graft biop-
sies, originating from 116 grafts in 114 patients, and taken for reasons of oliguria persisting 
for more than 10 days after transplantation, deteriorating renal graft function, or protein-
uria, the WT14 staining was scored blindly, without knowledge of the clinical data. The 
extent of WT14 positivity was estimated as the percentage of positive peritubular staining 
in relation to the total cortical peritubular area in the section. The WT14 score was given 
in semiquantitative categories, covering a scale of 0-100%. By plotting the WT14 scores in 
a ROC (receiver operating characteristic) curve it was possible to determine the optimal 
cutoff for the diagnosis "rejection", which resulted in a WT14 positivity of 70% of the sec-
tion area. By a similar procedure the optimal cutoff for the diagnosis "no rejection" was 
determined at 40%. By using these cutoffs and comparing the results with the original his-
tological diagnosis, the WT14 diagnosis of rejection had a positive predictive value of 9 1 % , 
a negative predictive value of 56%, a sensitivity of 70%, and a specificity of 85%. 
Comparing the WT14 diagnosis of rejection with the histological diagnosis according to 
the Banff criteria, these percentages were respectively 95%, 47%, 67%, and 90%, while 
comparing of the WT14 diagnosis with the definitive clinical diagnosis resulted in the 
respective percentages 84%, 63%, 72%, and 78%. The WT14 diagnosis essentially correc-
ted the original histological diagnosis in 7 cases, and was consistent with the eventual diag-
nosis in 5 equivocal cases. Comparison of HLA-DR expression on TEC with the Banff his-
tological diagnosis showed that in 108 of 113 cases with acute rejection tubular HLA-DR 
expression was increased, while in the group with a Banff diagnosis of no rejection HLA-DR 
staining was scored as positive in 36 of 38 cases. This results in a sensitivity of increased 
HLA-DR staining of TEC as a marker for rejection of 96%, a specificity of 5%, with a pre-
dictive value of 75% for a positive test and 29% for a negative one. From these data, given 
in chapter 4, we concluded that the extent of peritubular increase of WTl4-positive cells is 
directly related to the probability of acute rejection, and can be used as an additional crite-
rion in histologically difficult cases. 
Chapter 5 describes the results of an evaluation of the value of the Banff criteria for 
the histological diagnosis of rejection. The Banff classification was designed by Solez and 
coauthors in 1993 in an attempt to come to a reproducible classification schema that can 
be used to guide therapeutical interventions, and to predict graft outcome. In a series of 210 
adequate renal graft biopsies we compared the histological diagnosis, blindly scored according 
131 
to the Banff criteria, with the final clinical diagnosis that was made retrospectively, and divi­
ded in the categories: acute rejection, probable acute rejection, equivocal rejection, chronic 
rejection, and no rejection. When the diagnoses acute rejection and probable acute rejec­
tion were taken together and considered as clinical rejection, the Banff criteria pointed to a 
correct diagnosis in 114 of the 130 rejection episodes, and in 46 of 80 cases without acute 
rejection. It can be concluded that the Banff classification system can serve as an acceptable 
guideline for a standardized histological diagnosis of renal allograft rejection. A major short­
coming of the schema, however, is its overestimation of the diagnosis of acute rejection. 
Furthermore, in 14 of the 38 cases with borderline changes in the biopsy, the final clinical 
diagnosis was acute rejection. Thus, the advice given by Solez et al. that borderline changes 
are insufficient to justify antirejection treatment must be interpreted with caution. For the 
important discrimination between mild rejection (grade I rejection) and innocent infiltrates 
that, as shown by Rush et al. , occur in as much as 30% of biopsies in patients with stable 
graft function, further fine tuning of the Banff criteria and/or the use of accessory tech­
niques, such as immunohistology, are necessary. A published comment is reproduced as 
chapter 6. 
The immunocytological examination of urinary sediments (UIC) in the diagnosis of 
rejection of renal allografts is the subject of studies described in the third part of this thesis. 
The first study of this series, described in chapter 7, was a pilot study meant to investigate 
whether immunocytology on urinary sediments is feasible and whether increased HIA-DR 
expression on TEC and Τ lymphocytosis, as observed in FNABs and core biopsies of 
patients with rejection, is also reflected in the cells appearing in the urine. Cytospin prepa­
rations of 65 urinary sediments of kidney allograft recipients were incubated with MoAbs 
against Τ cell markers ( T i l , UCHL1) and HLA-DR in an indirect alkaline phosphatase 
technique. The presence of Τ lymphocytes together with an increased HLA-DR expression 
on TEC was considered to indicate acute rejection. Of 23 sediments (collected in 20 
patients) with immunocytological signs of rejection, 19 correlated with clinical and/or his­
tological signs of rejection, while four patients did not demonstrate any clinical signs of 
rejection. In 42 sediments (collected in 18 patients) no signs of rejection were present which 
was correct in 38 of these 42, while in four the results were false-negative. These data indi­
cated that this immunocytological examination of urinary sediments (UIC) might be a 
reliable, simple and noninvasive diagnostic procedure for monitoring rejection. 
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In a subsequent study, described in chapter 8, we tested whether the immunocytolo-
gical analysis of urinary sediments can be used to discriminate acute rejection from other 
causes of declining graft function. To this end, we retrospectively selected a series of speci­
mens that were collected at the time of increasing serum creatinine levels, as part of a larger 
series. In a total of 98 specimens we compared the immunocytological diagnosis, made 
without knowledge of clinical data, with the final clinical diagnosis. An immunocytological 
diagnosis "rejection" was made when an evident Τ lymphocytosis was seen together with a 
definite increase in HLA-DR expression on TEC. A diagnosis "probable rejection" was 
made if only one parameter was clearly positive. Twenty four specimens were inadequate. 
In 44 of 74 évaluable cases an immunocytological diagnosis of rejection was made, which 
was correct in view of the clinical outcome in 37. In 28 of 30 cases the immunocytological 
diagnosis "no rejection" proved to be correct. This indicates a sensitivity of 95% and a spe-
cificity of 80% for the immunocytological diagnosis of rejection. When comparing with the 
histological diagnosis (available in 38 patients) these statistical parameters were even higher: 
a sensitivity of 97% and a specificity of 83%. Urinary immunocytology therefore is of value 
in discriminating acute rejection from other causes of declining graft function. 
The next step was to determine whether sequential UIC can be used to monitor acute 
rejection in daily practice (chapter 9). To answer this question we examined urinary sedi-
ments at regular intervals in a group of 121 renal transplant recipients during the first 6 post 
transplantation months. Again, microscopic examination was blinded and retrospectively 
correlated with clinical and histologic data. Overall, the percentage of inadequate urine 
samples was 28%. In seventy-two patients (59%) a clinical acute rejection developed. In 57 
of 72 rejection episodes adequate urinary specimens were available. In 51 of these 57 cases 
(90%), the UIC diagnosis was correct (38x acute rejection, 13x probable rejection). In 3 of 
the 6 false-negative UIC diagnoses the concomitant renal biopsy showed an acute vascular 
rejection without interstitial infiltration. In 23 of 51 cases with clinical and cytological 
acute rejection the UIC diagnosis (acute rejection or probable rejection) preceded the cli-
nical signs of acute rejection by 2-35 days (mean 11 ± 2 (SEM)). In 49 stable patients, in 
whom clinical rejection did not develop, UIC was positive in 3 1 % of the samples (345 of 
1098 samples, l43x acute rejection and 202x probable rejection). The low incidence of 
false-negative diagnoses makes UIC a sensitive method to rule out acute rejection. The high 
incidence of false-positive diagnoses is in accordance with previously reported findings in 
sequential core biopsies ' . It limits the diagnostic value of UIC, especially in the absence 
of clinical signs of rejection. 
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CONCLUDING REiMARKS 
In our hands WT14 staining is a valuable adjunct in the diagnosis of acute rejection. 
A WT14 positivity of 70% or more of the total cortical peritubular area indicates rejection, 
whereas a WT14 score of < 40% makes rejection unlikely. At present, we routinely perform 
a WT14 staining in all graft biopsies that are of a sufficient size to be separated in different 
parts for histology, immunohistology, and electron microscopy if indicated. Staining results 
are available within 24 h, simultaneously with the conventional slides. In a sizeable num-
ber of difficult cases the result of the WT14 staining is the decisive factor for the clinician 
to start antirejection treatment or, alternatively to withhold such treatment. Scoring of the 
WT14 staining is more easily done and superior to the KP1 staining on routinely proces-
sed biopsies, in which the extent of positivity is not visible at first glance. The time-consu-
ming procedure of counting KP 1-positive cells per mm makes it unfeasible for routine 
daily diagnosis. In addition the staining procedure causes an extra delay of 24 h. The only 
disadvantage of the WIT 4 staining is that it requires material for frozen sections. 
Initially the results of the urinary immunocytology were rather promising: the test 
method had a high sensitivity and seemed to be attractive for use as a standard procedure 
in monitoring rejection. Our longitudinal UIC study indeed again demonstrated a low 
incidence of false-negative diagnoses, which makes UIC a sensitive method to rule out 
acute rejection. A predominantly vascular acute rejection with minimal or no interstitial 
infiltrate, however, may escape detection, like it may do in FNABs, and sometimes even in 
core biopsies due to sampling error. Although the sensitivity of the UIC can possibly be 
improved by using more or other markers , or by the use of flow immunocytometry , the 
problem of diagnosing acute vascular rejection will most likely not be solved with these 
techniques. Another important finding of our longitudinal, sequential study was the fact 
that the low specificity of positive findings forms a major drawback in the use of UIC. One 
should realize, however, that this high incidence of false-positive diagnoses is also encoun-
tered with other diagnostic techniques, and occurs even with the use of protocol core 
biopsies ' . For daily practice it means that a positive UIC diagnosis does not necessarily 
indicate ongoing rejection, but probably indicates that an inflammatory reaction is present 
in the allograft. Like in the studies of Rush et al., who compared graft survival and function 
between groups of renal transplant recipients with and without increased immunosuppres-
sion solely based on findings in protocol biopsies, the possible clinical relevance of a posi-
tive UIC diagnosis in the absence of clinical rejection has to be assessed in future studies. 
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For the moment improvements of the UIC as a diagnostic tool for acute rejection should 
concentrate on automation and standardization with the use of a panel of markers (T cell 
markers, HLA-DR, and activation markers, such as CD25 and CD54). The use of flow 
immunocytometry that we are currently studying, may allow for a more rapid analysis thus 
providing a solution for the substantial workload of performing and examining multiple 
immunocytological stainings in large numbers. 
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SAMENVATTING 
Patiënten met zeer slecht werkende nieren moeten indien hun nierfunctie beneden een 
bepaald niveau is gedaald starten met nierfunctievervangende therapie. Zij hebben dan de 
keuze uit hemodialyse (kunstnierbehandeling), peritoneale dialyse (buikspoeling) en nier-
transplantatie. Niertransplantatie is op termijn de beste behandeling, omdat dit leidt tot een 
betere kwaliteit van leven en, ook niet onbelangrijk, op den duur goedkoper is dan chroni-
sche dialysebehandeling. Wereldwijd zijn er inmiddels meer dan 30.000 niertransplantaties 
verricht. De resultaten hiervan zijn door de jaren heen verbeterd. Circa 85% van de ont-
vangers bezit 1 jaar na transplantatie een voldoende functionerend transplantaat, na 5 jaar 
is dit percentage echter gedaald tot 60 à 70%. De reden hiervoor is het verloren gaan van 
transplantaatnieren door een chronische rejectie (afstoting). Een belangrijke oorzaak voor 
het ontstaan van deze, meestal sluipend verlopende, niet behandelbare, chronische rejectie 
is het optreden van één of meer acute rejecties (snel optredende afstotingsreacties). De ont-
vanger beschouwt de transplantaatnier namelijk als lichaamsvrcemd en brengt zijn afweer-
apparaat er tegen in stelling. Deze acute rejecties kunnen in het algemeen goed behandeld 
worden, mits zo snel mogelijk gestart wordt met extra middelen die de afweer sterk onder-
drukken. Het is daarom van groot belang dat een acute rejectie in een zo vroeg mogelijk sta-
dium herkend wordt. Een acute rejectie is niet moeilijk te herkennen indien deze "klassiek" 
verloopt: met optreden van koorts, een pijnlijk transplantaat en afnemende urineproductie 
met ophoping van afvalstoffen in het bloed. De introductie begin jaren tachtig van het nieu-
we afweerremmende middel Cyclosporine (CsA) heeft echter het opsporen van een acute 
rejectie moeilijker gemaakt. CsA heeft namelijk als bijwerking dat het de werking van de 
transplantaatnier kan doen verminderen. Daarnaast kunnen ook chirurgische complicaties, 
zoals een vernauwing van de overgang van de urineleider van de transplantaatnier naar de 
blaas of een vernauwing in de slagader die de transplantaatnier van bloed voorziet tot ver-
mindering van nierfunctie leiden. Kortom, het stellen van de diagnose rejectie is niet 
bepaald eenvoudig. Een veel gebruikt hulpmiddel om een afstoting op te sporen is om 
transplantaatnierweefsel, verkregen door via de huid aanprikken van de nier met een holle 
naald (biopsie), onder de microscoop te bekijken. In het geval van een "klassieke" afstoting 
zijn er in het nierweefsel velden van ontstekingscellen aanwezig die de tubuli (afvoerbuisjes 
in de nier) binnendringen (tubulitis) en/of zich hechten aan de binnenzijde van de kleine 
bloedvaatjes in de nier (arteritis). Helaas zijn de bevindingen bij microscopisch onderzoek 
lang niet altijd "klassiek" en daardoor niet eenvoudig te classificeren. Door de jaren heen is 
er daarom gezocht naar aanvullende diagnostische technieken. Een daarvan is het uitvoeren 
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van immunohistochemische Heuringen. Hierbij wordt m.b.v. specifieke antistoffen gezocht 
naar de aanwezigheid van één speciaal type cel of eiwit dat kenmerkend is voor een afsto-
tingsreactie. Een goede kandidaat leek aanvankelijk het HLA-DR antigeen (humaan leuko-
cyten antigeen, een verzameling eiwitten). HLA-DR antigeen bleek bij een acute afsto-
tingsreactie in grote hoeveelheden voor te komen op de tubulusepitheelcellen (cellen die 
samen de afvoerbuisjes in de nier vormen). Uit later onderzoek bleek echter dat deze toe-
name niet exclusief bij rejectie voorkomt en er zelfs bij kan ontbreken. Ontstekingscellen 
als Τ lymfocyten en macrofagen vormen een ander mogelijk doelwit voor immunohisto­
chemische kleuringen. Uit onderzoek (van fijne naald aspiraten uit transplantaatnieren 
waarbij enkel losse cellen worden opgezogen uit de nier) is namelijk gebleken dat beide 
celtypen in het geval van rejectie aanwezig zijn. De macrofagen worden ook in biopten uit 
transplantaatnieren bij acute rejectie gezien. Moeilijkheid was tot voor kort het specifiek 
aantonen van dergelijke ontstekingscellen in biopten, voornamelijk als gevolg van tekort­
komingen in de kleuringstechnieken. Met de ontwikkeling van de antistof WT14, een eiwit 
dat gericht is tegen macrofagen en monocyten (een verwant type ontstekingscel), in ons 
laboratorium kregen wij echter een antistof in handen die goed bruikbaar leek voor de 
diagnostiek. In een serie van speciaal hiervoor uitgezochte nierbiopten onderzochten wij 
daarom de lokalisatie en mate van WT14 aankleuring (hoofdstuk 2). Alle 44 biopten 
afkomstig van patiënten met een acute rejectie toonden een diffuse toename van WT14-
positieve cellen in het interstitium (dat·deel van de nier dat zich tussen de tubuli bevindt), 
met een karakteristieke rangschikking rond de buisjes (peritubulair). Dit typische beeld 
ontbrak in 10 normale nieren, in 9 biopten afkomstig van patiënten met een nierbeschadi-
ging door CsA, in 13 biopten met een chronische afstoting en in 60 nierbiopten afkomstig 
van patiënten met diverse nierziekten. Ter vergelijking werd in deze reeks biopten ook de 
HLA-DR aankleuring bestudeerd. Deze bleek duidelijk een minder goed onderscheidend 
vermogen te hebben dan de WT14 kleuring. Zo toonden 5 van de 8 biopten met nierbe-
schadiging door CsA een toegenomen hoeveelheid HLA-DR antigeen op de tubulusepi-
theelcellen, evenals 11 van de 13 biopten met chronische afstoting en zelfs 39 van de 60 
nierbiopten afkomstig van patiënten met diverse nierziekten. Tevens bleek WT14 in deze 
serie superieur aan andere anti-monocyt/macrofaag antistoffen. Een belangrijk nadeel van 
WT14 is echter dat deze antistof alleen toepasbaar is op vriescoupes, waardoor een extra 
groot transplantaatnierbiopt vereist is. 
Een veelbelovend alternatief leek dan ook de nieuwe anti-monocyt/macrofaag antistof 
KP1, die in tegenstelling tot WT14 bruikbaar is op routinematig bewerkte nierbiopten. In 
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hoofdstuk 3 beschrijven we de resultaten van deze KPl kleuring op 27 geselecteerde en op 
de normale manier gefixeerde transplantaatnierbiopten: 16 rejectiebiopten en 11 controle-
biopten zonder acute rejectie. Met behulp van een telrooster werden, bij sterke vergroting, 
de KPl-positieve cellen geteld in 10 representatieve gebieden in het biopt. In 14 rejectie-
biopten was het aantal KPl-positieve cellen significant hoger dan in de controlebiopten. 
Twee rejectiebiopten toonden totaal geen aankleuring, waarschijnlijk door een te langdurige 
fixatie (weekend). Wij concludeerden hieruit dat de KPl kleuring een welkome aanvulling 
kan zijn voor de rejectiediagnostiek, met name in die gevallen waarin vriescoupemateriaal 
ontbreekt. 
In een volgende studie, beschreven in hoofdstuk 4, werd de diagnostische waarde van 
de WT14 kleuring voor de diagnose acute interstitiële rejectie beoordeeld. Hiertoe werd in 
154 transplantaatnierbiopten de uitgebreidheid van peritubulaire WT14 aankleuring ver-
geleken met a) de oorspronkelijke histologische diagnose, die met kennis van de klinische 
gegevens werd gesteld, b) de retrospectief en zonder kennis van de kliniek gestelde histolo-
gische diagnose volgens de Banff criteria (een recent geïntroduceerd schema voor de classi-
ficatie van histologische bevindingen in transplantaatnieren), en c) de definitieve klinische 
diagnose. Hierbij werd de WT14 positiviteit gegradeerd in categorieën van 0-100%. Met 
behulp van een ROC curve, een statistische bewerking, werd het optimale afkappunt voor 
de diagnose "acute interstitiële rejectie" bepaald op 70% WT14 positiviteit, voor de diag-
nose "geen rejectie" op 40%. Met andere woorden: bij een WT14 score > 70% werd de 
diagnose "rejectie" gesteld, bij een score < 40% de diagnose "geen rejectie". Vergeleken met 
de oorspronkelijke histologische diagnose heeft de WT14 diagnose rejectie (score > 70%) 
een sensitiviteit van 70%, een specificiteit van 85% en een voorspellende waarde voor een 
positieve respectievelijk negatieve test van 9 1 % en 56%. Vergeleken wij de WT14 diagno-
se met de histologische diagnose volgens de Banff criteria dan waren deze percentages 
respectievelijk 67%, 90%, 95% en 47%, terwijl vergelijking met de definitieve klinische 
diagnose resulteerde in de percentages 72%, 78%, 84% en 63%. In dezelfde serie werd ook 
de waarde van HLA-DR positiviteit van tubulusepitheelcellen voor de rejectiediagnostiek 
bestudeerd door vergelijking met histologische en klinische diagnose. Hoewel gevoeliger 
dan de WT14 diagnose was deze rejectieparameter aanzienlijk minder specifiek. Wij con-
cludeerden uit deze studie dat de uitgebreidheid van peritubulaire aankleuring van WT14-
positieve cellen direct gerelateerd is aan de waarschijnlijkheid dat er een acute afstoting 
bestaat en dat de W T Ì 4 kleuring vooral nuttig kan zijn bij histologisch moeilijk te classifi-
ceren transplantaatnierbiopten. 
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In hoofdstuk 5 beschrijven we de resultaten van een evaluatie van de waarde van de 
zogenaamde Banff criteria voor de histologische rejectiediagnose. De Banff classificatie is in 
1993 geïntroduceerd met de bedoeling te komen tot een reproduceerbaar classificatie-schema 
dat richtlijnen geeft voor therapeutische interventies en dat de langetermijnprognose van 
het transplantaat voorspelt. In een serie van 210 transplantaatnierbiopten vergeleken we de 
histologische diagnose, die zonder kennis van klinische gegevens met behulp van de Banff 
criteria werd gesteld, met de definitieve klinische diagnose. De Banff diagnose bleek correct 
in 114 van de 130 acute rejectiebiopten en in 46 van de 80 biopten zonder acute rejectie. 
Hieruit blijkt dat de criteria zoals aangegeven in het Banff schema inderdaad een accep-
tabele leidraad voor gestandaardiseerde histologische rejectiediagnostiek vormen. Voor-
naamste zwakte van de Banff diagnose is echter het relatief grote aantal fout-positieve 
resultaten. Een tweede tekortkoming betreft de zogeheten "borderline"-gevallen, biopten 
gekenmerkt door slechts kleine hoeveelheden ontstekingscellen die in het transplantaat de 
tubuli binnendringen. Het relatief grote aantal gevallen binnen deze groep met een klinisch 
acute rejectie, vormt een sterk argument tegen de aanbeveling van de opstellers van het 
Banff schema om in geval van "borderline" afwijkingen niet over te gaan tot het geven van 
anti-afstotingsmiddelen. Een ander probleem is het feit dat in zo'n 30% van transplantaat-
nierbiopten afkomstig van patiënten met een stabiele nierfunctie Infiltraten (gebieden vol 
ontstekingscellen) voorkomen. Om deze zogenaamde "onschuldige" Infiltraten te onder-
scheiden van een milde acute rejectie (graad I acute rejectie volgens de Banff classificatie) is 
verdere verfijning van de Banff criteria, dan wel toepassing van additionele kleuringen 
noodzakelijk, zoals in hoofdstuk 6 ter discussie wordt gesteld. 
De voor de patiënt meest eenvoudige manier om rejecties op te sporen is, in theorie, 
onderzoek van urinemonsters. Dit vormt het onderwerp van studie in het 3e deel van dit 
proefschrift. De eerste studie, beschreven in hoofdstuk 7, was bedoeld om na te gaan of er 
in de urine van transplantaatnierontvangers aanwijzingen zijn te vinden voor het bestaan 
van een afstoting. In het verleden is door verscheidene auteurs aangetoond dat er bij rejec-
tie in de urine een toegenomen hoeveelheid lymfocyten, ontstekingscellen, en/of tubuluse-
pitheelcellen voorkomt. Met de toen gebruikelijke routinekleuringen waren deze celtypen 
echter vaak moeilijk te onderscheiden van andere cellen in de urine. Wij hebben daarom 
deze routinekleuringen uitgebreid met specifieke immunocytologische kleuringen, waarbij 
met antistoffen specifiek Τ lymfocyten respectievelijk HLA-DR antigeen, een speciaal 
eiwit, op tubulusepitheelcellen kunnen worden aangekleurd. Inderdaad bleek uit onder­
zoek van 65 urinemonsters dat er bij rejectie een toegenomen hoeveelheid Τ lymfocyten 
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naast een verhoogde aanwezigheid van het HLA-DR antigeen op uitgescheiden tubulus-
epitheelcellen in de urine aantoonbaar was. Deze parameters werden niet gezien in urines 
afkomstig van patiënten zonder rejectie. Deze bevinding suggereerde dat urineonderzoek 
bij transplantaatnierontvangers een betrouwbare, simpele en veilige test zou kunnen zijn 
om rejectie aan te tonen. 
Hierop voortbordurend onderzochten wij in een volgend onderzoek, beschreven in 
hoofdstuk 8, of dit urine-onderzoek bruikbaar is om, in geval van transplantaatnierfunc-
tieverlies, onderscheid te maken tussen rejectie en andere oorzaken. We onderzochten hier-
toe 98 urinemonsters van patiënten met nierfunctieverlies na transplantatie en vergeleken 
de urinediagnose met de uiteindelijke klinische diagnose. Van deze 98 waren 74 urine-
monsters geschikt voor beoordeling. De urinediagnose bleek betrouwbaar: er waren weinig 
fout-positieve (7/44) en nog minder fout-negatieve (2/30) resultaten. 
Een volgende stap was om na te gaan of regelmatig onderzoek van urinemonsters van 
transplantaatnierontvangers behulpzaam zou kunnen zijn om in de dagelijkse praktijk 
afstoting aan te tonen, of mogelijk zelfs te voorspellen. Hiertoe onderzochten wij op regel-
matige tijdstippen urinemonsters in een groep van 121 transplantaatnierontvangers gedu-
rende 6 maanden na niertransplantatie. In totaal ontstond er bij 72 patiënten (59%) een 
acute afstoting. Van 57 personen met een rejectie was urine voorhanden voor onderzoek. In 
51 van de 57 gevallen bleek de urinediagnose correct. Bij 23 van de 51 patiënten met zowel 
klinische diagnose als urinediagnose "acute rejectie" bleek bovendien in het urineonderzoek 
al rejectie aantoonbaar voordat er klinisch tekenen van rejectie zichtbaar waren. In een 
groep van 49 patiënten die klinisch geen enkel teken van rejectie vertoonden bleek echter 
de urinediagnose in 3 1 % van de gevallen positief voor rejectie te zijn. In hoofdstuk 9 
concluderen wij daarom dat dit urineonderzoek vooral nuttig is om bij een patiënt met 
klachten die niet te onderscheiden zijn van die bij een rejectie, een rejectie uit te sluiten. De 
fout-positieve urinebevindingen zijn waarschijnlijk een afspiegeling van de zogenaamde 
"onschuldige" Infiltraten in transplantaatnierbiopten. Het veelvuldig voorkomen van fout-
positieve urinediagnosen beperkt echter de waarde van dit urineonderzoek, zeker bij patiën-
ten zonder klinische tekenen van afstoting. 
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DANKWOORD 
Nu het proefschrift zijn voltooiing nadert en alle artikelen, figuren en tabellen bij 
elkaar gezet moeten worden, besefik weer hoeveel mensen er hun bijdrage aan hebben gele-
verd. Eenieder wil ik voor zijn of haar hulp bedanken. Een aantal wil ik met name noemen. 
Allereerst mijn promotor Prof. dr. R.A.P. Koene: Rob, voor dit onderzoek werd je oude en 
eeuwigdurende liefde (het urinesediment) in een eigentijds jasje gestoken en werd "urine 
Dooper" een begrip. Dank voor de stimulerende discussies, die hun start soms letterlijk 
tussen de soep en de aardappels vonden. 
Mijn co-promotor, Dr. M.J.J.T Bogmam José, je voortdurend kritisch commentaar en ver-
zoek om nieuwe versies brachten me wel eens tot wanhoop. Gelukkig boden onze gesprek-
ken over de meest uiteenlopende onderwerpen voldoende aangenaam tegenwicht. 
En dan was daar natuurlijk altijd mijn andere co-promotor, Dr. A.J. Hoitsma: Andries, 
door je nuchter relativeringsvermogen wist je me weer op te peppen voor de volgende klus, 
al moet ik bekennen dat het behalen van mijn "International Sailing Licence" me wel iets 
gemakkelijker afging. Misschien komt er toch nog eens een fokkenistenplaatsje vrij ? 
Verder wil ik mijn analisten Trudi Machielsen, Hans Peters en Marcel Beukeboom bedanken 
voor hun bereidwilligheid om al die eindeloze stromen sedimenten en FNAB's tot fraaie 
coupes te verwerken. Trudi, tevens bedankt voor je hulp bij het opslaan en verwerken van 
alle urine-gegevens. 
Ook Cathy Maass en alle andere medewerkers van het IF-lab wil ik bedanken. Cathy, jij 
hebt me wegwijs gemaakt in het labjargon en je hebt opgewekt de eerste pilots voor je reke-
ning genomen. 
Oda Wolf en haar collega's wil ik bedanken voor het bewerken en snijden van hele series 
transplantaatbiopten. 
Karel Assmann, van jou heb ik de beginselen van de nefropathologie geleerd, bedankt daar-
voor. 
Dr. Wil Tax, Wim Tamboer en Cor Jacobs van het lab Nierziekten wil ik bedanken voor 
hun hulp bij het opzetten van ELISA's en flowcytometrie. 
Henri Dijkman, bedankt voor je fraaie immunoelectronenmicroscopische werk. 
Alle andere medewerkers van het ΡΑ-lab wil ik bedanken, in het bijzonder mijn kamerge­
noten van weleer, Rose-Marie Termaat en Geert Feith, voor de gezellige sfeer. 
En ook al werd ik op congressen steevast voor patholoog versleten, al die jaren bleef ik toch 
gelukkig internist. Ik wil dan ook vooral mijn patiënten bedanken voor hun bereidwillig-
heid om mij, waar mogelijk, van dienst te zijn met het inleveren van alweer een potje urine. 
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Verder gaat mijn dank ook uit naar de verpleging van de polikliniek Inwendige ziekten, de 
huidige post geel, en van afdeling E20, voor de hulp bij het verzamelen van alle benodigde 
materiaal. 
Mijn collega's van de afdeling Nierziekten wil ik bedanken voor de collegiale en kritische 
sfeer die er op onze afdeling heerst, waardoor het er prettig toeven is. 
Mijn ouders wil ik bedanken voor hun stimulerende houding en steun, mijn broer Marten 
voor het leesbaarder maken van mijn Nederlandse samenvatting. 
Diny en Wil, bedankt dat jullie ons huishouden op rolletjes laten lopen. 
Floortje en Sietze, jullie aanwezigheid heeft de loop van het onderzoek zeker niet bespoe-
digd, maar ontegenzeggelijk voor de nodige afleiding gezorgd ! Ga daar vooral mee door. 
Ton, natuurlijk had jij, als studievriend van het eerste uur, ex-collega internist, collega-
onderzoeker en collega-ouder, mijn paranimf moeten zijn. Helaas heb jij op 15 september 
andere verplichtingen! Hoe dan ook, ik ben er zeker van dat wij daarna samen het glas zullen 
heffen op deze tweeling. 
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CURRICULUM VITAE 
Ine(ke) Dooper werd op 19 februari 1956 in Kerkrade geboren. Nadat zij in 1974 het 
eindexamen Atheneum В had behaald aan het Sint Antonius Doctor College te Kerkrade, 
startte zij met de studie geneeskunde aan de Katholieke Universiteit te Nijmegen. Het doc­
toraalexamen behaalde zij in 1979, het artsexamen in 1981. Vanaf 1 december 1981 tot 
1 april 1986 was zij in opleiding tot internist in het Sint Joseph Ziekenhuis, toen nog in 
Eindhoven (opleider destijds dr. P.F.L. Deckers). Vanaf 1 april 1986 werd de opleiding voort­
gezet in het Academisch Ziekenhuis Nijmegen (opleider destijds Prof. dr. A. van 't Laar). Op 
de afdeling Nierziekten werd zij vanaf 1 april 1986 opgeleid voor het aandachtsgebied 
nefrologie (opleider Prof. dr. R.A.P. Koene). Op 1 december 1986 vond registratie plaats als 
internist. Op 1 november 1988 startte zij met het in dit proefschrift beschreven onderzoek. 
Vanaf 1993 is zij werkzaam op de polikliniek Nierziekten. Zij is getrouwd met Ton Naber. 
Samen zijn zij de ouders van Floortje en Sietze. 
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STELLINGEN 
1. De WT14 kleuring op transplantaatnierbiopten is een waardevolle aanwinst voor de 
rejectiediagnostiek (dit proefschrift). 
2. Nauwgezet onderzoek van het urinesediment bij patiënten met hématurie kan over-
bodig en belastend urologisch onderzoek voorkomen en verdient daarom meer aan-
dacht (BE van der Snoek et al. NedTijdschr Geneeskd 1994; 138: 721-726). 
3. Bij transplantaatnierontvangers met klinische symptomen die kunnen duiden op de 
aanwezigheid van een afstoting is immunocytologisch onderzoek van het urinesediment 
met name nuttig om een rejectie uit te sluiten (dit proefschrift). 
4. Immunocytologisch onderzoek van het urinesediment is niet bruikbaar als screenings-
methode om rejecties op te sporen in transplantaatnierontvangers (dit proefschrift). 
5. De voornaamste zwakte van de Banff classificatie, die criteria voor de histologische 
rejectiediagnose geeft, is het relatief grote aantal fout-positieve diagnosen (dit proef-
schrift). 
6. Het is gerechtvaardigd om bij niertransplantaties gebruik te maken van nieren afkom-
stig van levende, niet-verwante donoren, aangezien hierbij betere resultaten worden ver-
kregen dan bij transplantaties met postmortale nieren (PI Terasaki et al. N Engl J Med 
1995;333:333-336). 
7. Hypokaliëmische periodieke paralyse is in West-Europa een weinig bekende com-
plicatie van een doorgaans weinig opvallende hyperthyreoïdie (PhMM Dooper, 
PGG Gerlag, Ned Tijdschr Geneeskd 1984; 128: 117-118). 
8. Niet zozeer de camera als wel de blik van de fotograaf maakt de foto. 
9. Planologen en stedebouwkundigen zouden verplicht moeten worden op gezette tijden 
hun werkterrein achter kinderwagen dan wel in rolstoel te doorkruisen. 
10. De huidige klassegrootte in de onderbouw van het basisonderwijs is veeleer een argu-
ment voor verhoging dan verlaging van de leerplichtige leeftijd. 
11. Een voordeel dat bestudering van microscopische coupes biedt boven het klinisch 
onderzoek van patiënten is dat eerstgenoemde gecombineerd kan worden met het 
beluisteren van muziek. 
12. Varkenspest is niet Normaal. 
13. Het uitreiken van volgnummers kan veel ergernis bij een drukke sluis wegnemen. 
14. Gedeelde smart is dubbele smart (onze proefschriften). 
15 september 1997 
Ine Dooper 


